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A B S T R A C T
Background
Ketogenic diets (KDs) are high in fat and low in carbohydrates and have been suggested to reduce seizure frequency in people with epilepsy.
Such diets may be beneficial for children with drug-resistant epilepsy.
This is an update of a review first published in 2003, and last updated in 2018.
Objectives
To assess the eIects of ketogenic diets for people with drug-resistant epilepsy.
Search methods
For this update, we searched the Cochrane Register of Studies (CRS Web) and MEDLINE (Ovid, 1946 to 26 April 2019) on 29 April 2019.
The Cochrane Register of Studies includes the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled
Trials (CENTRAL), and randomised controlled trials (RCTs) from Embase, ClinicalTrials.gov and the World Health Organization (WHO)
International Clinical Trials Registry Platform (ICTRP). We imposed no language restrictions. We checked the reference lists of retrieved
studies for additional relevant studies.
Selection criteria
RCTs or quasi-RCTs of KDs for people of any age with drug-resistant epilepsy.
Data collection and analysis
Two review authors independently applied predefined criteria to extract data and evaluated study quality. We assessed the outcomes:
seizure freedom, seizure reduction (50% or greater reduction in seizure frequency), adverse eIects, cognition and behaviour, quality of
life, and attrition rate. We incorporated a meta-analysis. We utilised an intention-to-treat (ITT) population for all primary analyses. We
presented the results as risk ratios (RRs) with 95% confidence intervals (CIs).
Main results
We identified 13 studies with 932 participants; 711 children (4 months to 18 years) and 221 adults (16 years and over).
We assessed all 13 studies to be at high risk of performance and detection bias, due to lack of blinding. Assessments varied from low to
high risk of bias for all other domains. We rated the evidence for all outcomes as low to very low certainty.
Ketogenic diets versus usual care for children
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Seizure freedom (RR 3.16, 95% CI 1.20 to 8.35; P = 0.02; 4 studies, 385 participants; very low-certainty evidence) and seizure reduction
(RR 5.80, 95% CI 3.48 to 9.65; P < 0.001; 4 studies, 385 participants; low-certainty evidence) favoured KDs (including: classic KD, medium-
chain triglyceride (MCT) KD combined, MCT KD only, simplified modified Atkins diet (MAD) compared to usual care for children. We are
not confident that these estimated eIects are accurate. The most commonly reported adverse eIects were vomiting, constipation and
diarrhoea for both the intervention and usual care group, but the true eIect could be substantially diIerent (low-certainty evidence).
Ketogenic diet versus usual care for adults
In adults, no participants experienced seizure freedom. Seizure reduction favoured KDs (MAD only) over usual care but, again, we are
not confident that the eIect estimated is accurate (RR 5.03, 95% CI 0.26 to 97.68; P = 0.29; 2 studies, 141 participants; very low-certainty
evidence). Adults receiving MAD most commonly reported vomiting, constipation and diarrhoea (very low-certainty evidence). One study
reported a reduction in body mass index (BMI) plus increased cholesterol in the MAD group. The other reported weight loss. The true eIect
could be substantially diIerent to that reported.
Ketogenic diet versus ketogenic diet for children
Up to 55% of children achieved seizure freedom with a classical 4:1 KD aDer three months whilst up to 85% of children achieved seizure
reduction (very low-certainty evidence). One trial reported a greater incidence of seizure reduction with gradual-onset KD, as opposed to
fasting-onset KD. Up to 25% of children were seizure free with MAD and up to 60% achieved seizure reduction.
Up to 25% of children became seizure free with MAD and up to 60% experienced seizure reduction. One study used a simplified MAD (sMAD)
and reported that 15% of children gained seizure freedom rates and 56% achieved seizure reduction. We judged all the evidence described
as very low certainty, thus we are very unsure whether the results are accurate.
The most commonly reported adverse eIects were vomiting, constipation and diarrhoea (5 studies, very low-certainty evidence). Two
studies reported weight loss. One stated that weight loss and gastrointestinal disturbances were more frequent, with 4:1 versus 3:1 KD,
whilst one reported no diIerence in weight loss with 20 mg/d versus 10 mg/d carbohydrates. In one study, there was a higher incidence of
hypercalcuria amongst children receiving classic KD compared to MAD. All eIects described are unlikely to be accurate.
Ketogenic diet versus ketogenic diet for adults
One study randomised 80 adults (aged 18 years and over) to either MAD plus KetoCal during the first month with MAD alone for the second
month, or MAD alone for the first month followed by MAD plus KetoCal for the second month. No adults achieved seizure freedom. More
adults achieved seizure reduction at one month with MAD alone (42.5%) compared to MAD plus KetoCal (32.5%), however, by three months
only 10% of adults in both groups maintained seizure reduction. The evidence for both outcomes was of very low certainty; we are very
uncertain whether the eIects are accurate.
Constipation was more frequently reported in the MAD plus KetoCal group (17.5%) compared to the MAD only group (5%) (1 study, very
low-certainty evidence). Diarrhoea and increase/change in seizure pattern/semiology were also commonly reported (17.5% to 20% of
participants). The true eIects of the diets could be substantially diIerent to that reported.
Authors' conclusions
The evidence suggests that KDs could demonstrate eIectiveness in children with drug-resistant epilepsy, however, the evidence for the
use of KDs in adults remains uncertain. We identified a limited number of studies which all had small sample sizes. Due to the associated
risk of bias and imprecision caused by small study populations, the evidence for the use of KDs was of low to very low certainty.
More palatable but related diets, such as the MAD, may have a similar eIect on seizure control as the classical KD, but could be
associated with fewer adverse eIects. This assumption requires more investigation. For people who have drug-resistant epilepsy or who
are unsuitable for surgical intervention, KDs remain a valid option. Further research is required, particularly for adults with drug-resistant
epilepsy.
P L A I N   L A N G U A G E   S U M M A R Y
Ketogenic diets for drug-resistant epilepsy
Background
Epilepsy is a disorder where recurrent seizures are caused by abnormal electrical discharges from the brain. In most people, seizures can
be controlled by one or more antiepileptic medicines. For people who continue to have seizures (drug-resistant epilepsy) a special diet, a
ketogenic diet, may be considered. Ketogenic diets are high in fat and low in carbohydrate.
This review looked at the eIects of ketogenic diets on seizure control, learning and memory, and behaviour. We also investigated the side
eIects of the diet and the number of people who withdrew from studies, plus the reasons why.
Study characteristics
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We searched medical databases for clinical trials of adults or children with epilepsy, where a ketogenic diet was compared with other
treatments. We found 13 trials, with 932 participants. The trials were between two and 16 months long.
Key results
Children given ketogenic diets may be up to three times more likely to achieve seizure freedom and up to six times more likely to experience
a 50% or greater reduction in seizure frequency compared to children given their usual care. Although the rates of seizure freedom reported
by most of the studies were fairly modest, in one study over half of the children given a classical ketogenic diet became seizure free. This
rate reduced to only 15% of children achieving seizure freedom when they were given a less restrictive modified Atkins diet. Another study
reported that 85% of children given a classical ketogenic diet had a significant reduction in their number of seizures compared to only
around half of children who received a modified Atkins diet. One study, however, found similar eIects on seizure control with the better
tolerated modified Atkins diet as with the more restrictive ketogenic diet, highlighting that more research is required.
There were no reports of seizure freedom in adults following ketogenic diets, however, adults given ketogenic diets may be up to five times
more likely to experience a 50% or greater reduction in seizure frequency.
All studies reported people dropping out due to lack of improved seizures and poor tolerance of diet. Adults following ketogenic diets may
be up to five times more likely to drop out of studies compared with usual care. For children, dropout rates may be similar in ketogenic
diet and usual care treatment groups.
One study reported the eIects of ketogenic diets on quality of life, learning, memory, and behaviour in children. The study suggested no
diIerence in the quality of life of children following a ketogenic diet and those receiving usual care. Children following ketogenic diets were
suggested to be more active, more productive and less anxious, but more research is needed.
Certainty of the evidence
The trials only included a small number of people and their methods were unclear. We therefore judged the certainty of the evidence to
be low to very low. This means that we are not confident that the results described are accurate of the true eIect of ketogenic diets in
people with epilepsy.
This evidence is current to April 2019.
Ketogenic diets for drug-resistant epilepsy (Review)



































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Ketogenic diet (KD) compared to usual care for children with drug-resistant epilepsy
Ketogenic diet (KD) compared to usual care for children with drug-resistant epilepsy
Patient or population: children (aged 1 to 18 years) with drug-resistant epilepsy
Setting: outpatients
Intervention: KD (including: classic KD (4:1), classic KD and MCT KD combined, MAD, MCT KD, and sMAD)
Comparison: control intervention (usual care)
Anticipated absolute effects* (95% CI)Outcomes
















(100% reduction in seizure
frequency)
Follow-up: 3 months to 4
months










Study population50% or greater reduction
in seizure frequency
Follow-up: 3 months to 4
months










Follow-up: 3 months to 4
months
The most frequent adverse effects reported by participants in dietary intervention groups were: vomiting,
constipation and diarrhoea. These adverse effects were also commonly reported by participants in the
usual care groups.
Other less common adverse effects reported included: dysphagia, lethargy, lower respiratory tract in-
fection, hyperammonaemic encephalopathy, weight loss, nausea, infections (pneumonia, sepsis), acute
pancreatitis, decrease in bone matrix density, gallstones, fatty liver, nephrocalcinosis, hypercholestero-
laemia, status epilepticus, acidosis, dehydration, tachycardia, hypoglycaemia, hunger, abdominal pain,








Children randomised to KD were more active (P = 0.005), more productive (P = 0.039) and less anxious (P =














































































































































Follow-up: 3 months to 6
months









*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; KD: ketogenic diet; MAD: modified Atkins diet; MCT: medium-chain triglyceride; QALY: quality of life-adjusted year; RCT: randomised controlled trial
RR: risk ratio; sMAD: simplified modified Atkins diet
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded once due to risk of bias: some included studies were not blinded, had missing data or unclear methodological details reported.
bDowngraded once due to imprecision: low overall sample size, plus low number of events (< 200). Confidence in results from small number of participants is low.
cDowngraded twice due to imprecision: low overall sample size, plus low number of events (< 50). Confidence in results from small number of participants is low.
dDowngraded once due to imprecision: a narrative synthesis was used for this outcome.
 
 
Summary of findings 2.   Ketogenic diet (KD) compared to usual care for adults with drug-resistant epilepsy
Ketogenic diet (KD) compared to usual care for adults with drug-resistant epilepsy
Patient or population: adults (aged 16 years and over) with drug-resistant epilepsy
Setting: outpatients
Intervention: KD (modified Atkins diet (MAD))
Comparison: control intervention (usual care)
Anticipated absolute effects* (95% CI)Outcomes











































































































































Follow-up: 2 months to 3
months
No adults in either the MAD or the usual care group achieved seizure freedom, therefore we were







Study population50% or greater reduction in
seizure frequency
Follow-up: 2 months to 3
months











Follow-up: 2 months to 3
months
Common adverse effects reported by participants receiving MAD were: vomiting, constipation
and diarrhoea. One study reported a significant reduction in BMI, as well as an increase in choles-
terol in the MAD group, whilst the other study reported significant weight loss. Other adverse ef-








Cognition and behaviour Outcome not reported N/A  
Quality of life Outcome not reported N/A  
Study populationTreatment withdrawal
Follow-up: 2 months to 3
months










*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
BMI: body mass index; CI: confidence interval; KD: ketogenic diet;MAD: modified Atkins diet; NA: not applicable; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded once due to risk of bias: some included studies were not blinded, had missing data or unclear methodological details reported.
bDowngraded twice due to imprecision: low overall sample size, plus low number of events (< 50). Confidence in results from small number of participants is low.
cDowngraded once due to imprecision: a narrative synthesis was used for this outcome.































































































































Summary of findings 3.   Ketogenic diets (KDs) compared with other KDs for children with drug-resistant epilepsy
Ketogenic diets (KDs) compared with other KDs for children with drug-resistant epilepsy
Patient or population: children (aged 4 months to 16 years) with drug-resistant epilepsy
Settings: outpatients
Intervention: KDs (fast KD, modified Atkins diet (MAD), MAD with 10 g per day carbohydrate limit, 4:1 (classic) KD)
Control: other KDs (gradual KD, classic KD, MAD with 20 g per day carbohydrate limit, 2.5:1 KD, 3:1 KD)
Illustrative comparative risks* (95% CI)


























Proportion of children achieving seizure freedom ranged from 10% to 25% on MAD. There was no infor-
mation about whether the seizure freedom varied depending on the restriction of carbohydrates (10
mg/d versus 20 mg/d). 21% of children on 2:5:1 KD achieved seizure freedom compared to 26% to 55%
on 4:1 KD and 35% on the 3:1 KD. 33% of children on a classic KD were seizure free at 3 months. 21% of

















The proportion of children achieving seizure reduction ranged from 42% to 60% on MAD, however, the
rate decreased to 10% when daily carbohydrate intake was increased to 20 mg/d, compared to 10 mg/
d. 43% of children on a classic KD achieved seizure reduction with 58% to 85% on 4:1 KD, 72% on the 3:1
KD and 63% on 2.5:1 KD. 58% on the fasting-onset KD and 67% on the gradual-onset KD attained 50% or




























The most frequent adverse effects reported by children were: vomiting, constipation and diarrhoea.
Two studies reported weight loss, with one study stating that weight loss and gastrointestinal distur-
bances were more frequently reported with 4:1 KD versus 3:1 KD. One study reported a significantly
high incidence rate for hypercalcuria amongst children receiving classic KD compared to MAD at three
months. There was no significant difference in weight loss between treatment groups given 20 mg/d
versus 10 mg/d carbohydrates.
Other adverse effects reported included: dysphagia, lethargy, lower respiratory tract infection, hyper-





































































































































bone matrix density, gallstones, fatty liver, nephrocalcinosis, hypercholesterolaemia, status epilepti-
cus, acidosis, dehydration, tachycardia, hypoglycaemia, hunger,abdominal pain, clinically relevant re-




Outcome not reported NA  
Quality of life
Follow-up: NA





Proportion of individuals withdrawing from KD groups were: 8% gradual-onset KD; 16% on 2:5:1 KD and









*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; KD: ketogenic diet;MAD: modified Atkins diet; NA: not applicable; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded once due to risk of bias: some included studies were not blinded, had missing data or unclear methodological details reported.
bDowngraded once due to inconsistency: studies are heterogeneous with regards to interventions examined and comparisons made.
cDowngraded once due to imprecision: low overall sample size, plus low number of events (< 200). Confidence in results from small number of participants is low.
dDowngraded twice due to imprecision: very low overall sample size, plus low number of events (< 50). Confidence in results from small number of participants is low.
eDowngraded once due to imprecision: a narrative synthesis was used for this outcome.
 
 
Summary of findings 4.   Ketogenic diets (KDs) compared with other KDs for adults with drug-resistant epilepsy
Ketogenic diets (KDs) compared with other KDs for adults with drug-resistant epilepsy
Patient or population: adults (aged 18 years and over) with drug-resistant epilepsy
Settings: outpatients





























































































































Control: other KDs (MAD alone in the first month, followed by MAD plus KetoCal during second month)
Illustrative comparative risks* (95% CI)























No adult participants achieved seizure freedom with either MAD plus KetoCal in month one (inter-































The proportion of adults achieving 50% or greater reduction in seizure frequency at one month was
32.5% for the intervention group (MAD plus KetoCal month one) and 42.5% for the control (MAD
plus KetoCal month two). This decreased to 25% versus 32.5%, respectively at two months. At three












Constipation was reported more frequently by adults in the MAD plus KetoCal group (17.5%) com-
pared to MAD only treatment group (5%). Diarrhoea and increase/change in seizure pattern/semi-
ology were also commonly reported (17.5% to 20% of participants). Other less commonly report-
ed adverse effects included: abdominal pain, headache, irregular menses, halitosis, somnolence,











Outcome not reported NA  

































































































































12.5% of adults withdrew from the intervention group (MAD plus KetoCal month one) compared to









*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; KD: ketogenic diet; MAD: modified Atkins diet; NA: not applicable; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded once due to risk of bias: the study did not appear to be blinded, it was not clear whether there was missing data. Unclear methodological details were reported.
bDowngraded twice due to imprecision: low overall sample size, plus low number of events (< 50). Confidence in results from small number of participants is low. Unable to
conduct a meta-analysis.
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B A C K G R O U N D
This is an update of a review first published in 2003 (Levy 2003), and
last updated in 2018 (Martin-McGill 2018).
Description of the condition
Epilepsy is a common treatable neurological condition with a
lifetime risk of 1% to 3% (Hauser 1990). It is characterised by
recurrent involuntary brain activity that manifests in seizures
(Chang 2003). Although the majority of people with epilepsy will
have a good response and become seizure free by treatment
with antiepileptic drugs (AEDs), approximately 30% of people
with epilepsy will continue to have seizures, even when taking
multiple AEDs; a condition referred to as drug-resistant epilepsy
(Granata 2009). Uncontrolled seizures pose a significant risk to
quality of life (Lawn 2004; Schmidt 2002; Villeneuve 2004). In
addition, uncontrolled tonic-clonic seizures are likely to be one
of the strongest risk factors of sudden death in epilepsy (Nilsson
1999). Therefore, it is important not to rely on pharmacological
interventions when treating drug-resistant epilepsy, and further
evidence for alternative interventions is needed.
Description of the intervention
Diets have been used in an attempt to control epileptic seizures
throughout the centuries, indeed there is a biblical reference
to prayer and fasting in epilepsy (St Mark 9: 14-29). Scientific
assessment of dietary manipulation reported in Guelpa 1911,
and subsequently in Geyelin 1921, confirmed that seizures may
cease on absolute fasting, but neither study was a randomised
controlled trial (RCT). Wilder 1921 suggested that a diet high in
fat and low in carbohydrates would be similar to fasting. The
classical ketogenic diet (KD) uses a 4:1 ratio of total energy
from fat to carbohydrate and protein combined. KDs have been
described as unpalatable and diIicult to tolerate, thus leading to
poor compliance. Therefore, several diets have been developed to
improve palatability, including those of lower ratios (such as 3:1),
the medium-chain triglyceride (MCT) KD (Huttenlocher 1971), and
the modified Atkins diet (MAD). The MCT KD allows for an increase
in carbohydrate and protein due to the potential to increase ketone
levels through the inclusion of MCT fats. The MAD, adapted from
the Aktins diet initially used for weight reduction (Atkins 1972),
restricts carbohydrate to 10 g to 20 g per day, and is considered less
restrictive than classical KDs.
Prior to the introduction of anticonvulsant medications (Merritt
1938), KDs were used in children (and adults) who were more
representative of the current general population of people with
epilepsy. However, case series published since the mid-1980s
have generally included people with multiple seizure types drug-
resistant to multiple AEDs. The classical KD and other more
palatable versions have a positive eIect on infantile spasms, severe
myoclonic epilepsy, tuberous sclerosis complex (KossoI 2005), and
children with drug-resistant status epilepticus (O'Connor 2014).
How the intervention might work
Although the anticonvulsant eIects of KDs remain unclear,
numerous biochemical theories have been suggested for the
possible action of the diet. These include the anticonvulsant eIects
of elevated ketone bodies, elevated fatty acids and reduced glucose
levels (Bough 2007), with further research ongoing in this field.
Why it is important to do this review
Despite the use of KDs for adults and children with drug-resistant
epilepsy within clinical settings, the number of high-quality RCTs
has been limited. Therefore, the evidence base for this intervention
has been unclear. This review aims to assess the eIectiveness of
KDs when considering evidence from RCTs, across all healthcare
settings, for both adults and children with drug-resistant epilepsy.
In this review we will include RCTs which compare KDs to usual care
and one KD to another KD.
O B J E C T I V E S
To assess the eIects of ketogenic diets for people with drug-
resistant epilepsy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials (RCTs) or quasi-RCTs
of ketogenic diet (KD) interventions for people with drug-resistant
epilepsy, with a minimum study period of one month.
Types of participants
Adults and children with a diagnosis of drug-resistant epilepsy,
irrespective of their seizure type or epilepsy syndrome. We did
not predefine what we considered to be adult or paediatric trial
populations. Instead, we followed the classification set by each
individual trial author team. Reflective of clinical services, in some
cases adults were defined as aged 16 years and over, whilst all
paediatric studies only included participants aged 18 years and
under.
For the first time, we also attempted to report on epilepsy
populations with intellectual disabilities.
Types of interventions
Ketogenic diet group (related diet)
• Any diet that is designed to produce ketones. There are several
KDs that have been used depending upon the proportion of the
diIerent types of lipids. The main types of diet are:
* classical KD;
* medium-chain triglyceride (MCT) KD;
* modified Atkins diet (MAD); and
* low glycaemic index treatment (LGIT).
• We also included studies which compared diIerent types of KDs
or diIerent KD regimes (fasting versus gradual initiation).
Usual care group
• Placebo/usual/sham diet given as a standard treatment that is
thought to have no eIect on epilepsy.
• Any treatment with known antiepileptic properties.
Types of outcome measures
Primary outcomes
• Seizure freedom (100% reduction in seizure frequency);
Ketogenic diets for drug-resistant epilepsy (Review)
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• Cognition and behaviour, as measured by validated rating
scales;
• Quality of life, as measured by validated rating scales;
• Attrition rate.
Search methods for identification of studies
Electronic searches
We ran searches for the original review in March 2005 and
subsequent searches in July 2007, January 2010, June 2011, March
2015, April 2017, and April 2019. For the most recent update of this
review we searched:
• the Cochrane Register of Studies (CRS Web, 29 April 2019) using
the search strategy outlined in Appendix 1;
• MEDLINE (Ovid, 1946 to April 26, 2019) using the search strategy
outlined in Appendix 2.
The Cochrane Register of Studies (CRS Web) includes the Cochrane
Epilepsy Group Specialized Register, the Cochrane Central Register
of Controlled Trials (CENTRAL), and randomised controlled trials
from Embase, ClinicalTrials.gov and the World Health Organization
(WHO) International Clinical Trials Registry Platform (ICTRP).
Searching other resources
We searched references from previous versions of this review
(backward referencing) and newer references from more up-to-
date studies. We contacted experts in the field to enquire about
other relevant studies.
Data collection and analysis
Selection of studies
Two review authors (KMM, RB) independently reviewed the titles
and abstract of the studies identified by the electronic searches
and removed studies that did not meet the inclusion criteria.
Two review authors (KMM, RB) reviewed the full-text reports to
determine eligibility. We resolved any disagreements by discussion.
In the event of there being multiple reports deriving from one study,
we linked the reports together.
Data extraction and management
In addition to the main outcome measures listed in Primary
outcomes and Secondary outcomes, two review authors (KMM,
RB) completed data extraction for each study. We cross-checked
results of the data extraction and resolved any disagreements by
discussion.
We also collected the following data using a pre-standardised data
extraction form.
• Participant characteristics including known learning disability,
age, sex and number of participants (randomised to each group);
• Diet intervention (type of KD);
• Length of follow-up;
• Epilepsy seizure type;
• Reason for commencement;
• Adverse eIects;
• Reason for drop out, including compliance.
Assessment of risk of bias in included studies
Two review authors (KMM, RB) independently assessed the risk of
bias and compared the results from these assessments to identify
any inconsistencies. We resolved any disagreements by discussion.
We judged whether each study was at high, low or unclear risk of
bias in each of the following domains.
• Random sequence generation;
• Allocation concealment;
• Blinding of participants and personnel;
• Blinding of outcome assessment;
• Incomplete outcome data;
• Selective outcome reporting;
• Other potential risks of bias.
Where possible, we planned to incorporate the risk of bias
judgement into the analysis using sensitivity analysis. This analysis
of the data would have included only studies rated at low risk of
bias.
Measures of treatment e8ect
We presented the dichotomous outcomes, namely seizure
freedom, 50% or greater reduction in seizure frequency, and
attrition, as risk ratios (RRs) with 95% confidence intervals (CIs). We
reported all other outcomes narratively.
For behaviour, quality of life, and cognitive outcomes, it was
unlikely that individual authors would have addressed this in a
uniform manner. In the first instance, we planned to summarise the
results using text and tables.
Unit of analysis issues
In the event of unit of analysis issues being identified across studies
(e.g. cross-over, cluster-randomised or repeated measures studies),
we planned to:
• determine whether the methods in such studies were conducted
appropriately; and
• combine extracted eIect sizes from such studies through a
generic inverse variance meta-analysis.
Dealing with missing data
In the event of missing data, we conducted an intention-to-treat
(ITT) analysis where possible, including all allocated participants
in the treatment groups to which they were allocated, irrespective
of the treatment they received. Where necessary, we contacted
original trial authors for additional data or clarification.
Assessment of heterogeneity
Two review authors (KMM, RB) assessed clinical and
methodological heterogeneity by investigating the distribution
of important prognostic factors between trials and their study
design. We assessed statistical heterogeneity using a Chi2 test (P <
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0.10) and an I2 statistic of greater than 50% to indicate statistical
heterogeneity in accordance with Cochrane guidelines (Higgins
2011).
Assessment of reporting biases
We investigated outcome reporting bias using the ORBIT matrix
system (Kirkham 2010). We requested all protocols from study
authors to compare outcomes of interest.
To examine publication bias, we identified any unpublished data
by carrying out a comprehensive search of multiple sources and
requesting unpublished data from study authors. We planned to
examine funnel plots in the event of there being 10 or more
studies that could be combined, in accordance with Cochrane
recommendations (Higgins 2011).
Data synthesis
In datasets which lacked heterogeneity (P ≥ 0.10), we conducted
a meta-analysis using a fixed-eIect model. Where we detected
significant heterogeneity (P < 0.10), we used a random-eIects
model. All meta-analyses, regardless of model used, utilised the
Mantel-Haenszel method.
We planned to carry out the following comparisons.
• KD compared with a usual care (standard of care and usual diet)
• KD compared with other dietary interventions
• KD compared with other interventions
• One KD compared with another KD intervention.
Meta-analysis was possible for KDs compared with a usual care
(standard of care and usual diet). We were unable to conduct
meta-analyses for the other comparisons due to the clinical
heterogeneity and limited data available.
Subgroup analysis and investigation of heterogeneity
We recognised clinical heterogeneity within the studies included in
the meta-analysis with regard to the age of the study population
used. For this reason, we completed a subgroup analysis according
to age, separating studies into those which investigated the use of
KDs in children and those that investigated the use of KDs in adults.
Sensitivity analysis
We intended to carry out sensitivity analysis if we found
peculiarities between study quality. We planned to report and
compare analyses for only the studies at low risk of bias, however,
all of the included studies were at substantial risk of bias.
Summary of findings and assessment of the certainty of the
evidence
We graded the evidence for each outcome using the GRADE
approach (Schünemann 2013), which is a formal process used to
rate the certainty of evidence for outcomes in systematic reviews.
We used the GRADEpro GDT soDware to import data from Review
Manager 5 soDware (GRADEpro 2015) and used it to create four
'Summary of findings' tables for all outcomes and comparisons: KD
compared to usual care for children with drug-resistant epilepsy
(Summary of findings 1); KD compared to usual care for adults with
drug-resistant epilepsy (Summary of findings 2); KDs compared
with other KDs for children with drug-resistant epilepsy (Summary
of findings 3); and KDs compared with other KDs for adults with
drug-resistant epilepsy (Summary of findings 4).
R E S U L T S
Description of studies
Results of the search
Previous versions of this review identified 11 randomised
controlled trials (RCTs) (Bergqvist 2005; El-Rashidy 2013; Kim 2016;
KossoI 2007; Lambrechts 2017; Neal 2008; Raju 2011; Seo 2007;
Sharma 2013; Sharma 2016; Zare 2017), and one ongoing study that
remains ongoing (CTRI/2015/07/006048).
The updated search from April 2019 revealed 139 studies
from the databases outlined in Electronic searches. ADer
removing duplicates, 111 studies remained. Initial screening
removed 99 irrelevant studies, leaving 12 studies. The remaining
studies underwent full-text review; we identified seven of
these as ongoing studies (CTRI/2017/12/010898; Hulshof 2017;
NCT02708030; NCT03764956; NCT03464487; NCT03807141; Titre-
Johnson 2017; see Characteristics of ongoing studies), and we
recognised that one publication was not a RCT (NCT03183076).
We therefore excluded the latter publication (see Characteristics of
excluded studies). We deemed two studies eligible for inclusion in
the present review update (Kverneland 2018; McDonald 2018; see
Characteristics of included studies). ADer the addition of the two
most recent trials, the review contains 13 studies from a total of 17
publications.
See Figure 1 for a PRISMA study flow diagram (Moher 2009).
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Figure 1.   Study flow diagram (results illustrate the latest update).
 
Included studies
We included 13 studies in this review (n = 932). These studies were
conducted across various healthcare systems worldwide. Seven
studies compared a ketogenic diet (KD) to a usual care group
(El-Rashidy 2013; Kverneland 2018; Lambrechts 2017; Neal 2008;
Sharma 2013; Sharma 2016; Zare 2017), and six studies compared
one KD intervention to another type of KD intervention (Bergqvist
2005; Kim 2016; KossoI 2007; McDonald 2018; Raju 2011; Seo
2007). A summary of studies included can also be found in the
Characteristics of included studies tables.
Methods
All 13 studies in this review were randomised controlled trials.
Twelve of the included studies were single-centre studies (Bergqvist
2005; El-Rashidy 2013; Kim 2016; KossoI 2007; Kverneland 2018;
Lambrechts 2017; McDonald 2018; Raju 2011; Seo 2007; Sharma
2013; Sharma 2016; Zare 2017) while one was a multi-centre
study (Neal 2008). Notably, however, the majority of participants
were recruited from a single, main centre. The included studies
were conducted in range of countries, namely: Egypt (El-Rashidy
2013); India (Raju 2011; Sharma 2013; Sharma 2016); Iran (Zare
2017); Korea (Kim 2016; Seo 2007); Netherlands (Lambrechts 2017);
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Norway (Kverneland 2018); United Kingdom (Neal 2008); and
United States of America (Bergqvist 2005; KossoI 2007; McDonald
2018). All of the studies used a parallel group design, with the
exception of one study (KossoI 2007) that utilised a cross-over
design.
Participants
A total of 932 participants were enrolled across the 13 included
studies. Ten of the studies investigated ketogenic diets for children,
aged 4 months to 18 years (Bergqvist 2005; El-Rashidy 2013; Kim
2016; KossoI 2007; Lambrechts 2017; Neal 2008; Raju 2011; Seo
2007; Sharma 2013; Sharma 2016), while three studies investigated
ketogenic diets for adults (Kverneland 2018; McDonald 2018; Zare
2017). Notably, one of the adult studies included participants as
young as 16 years old (Kverneland 2018). Despite this, we continued
to recognise the study as an adult only study. We considered this
to be reflective of the complexities and discrepancies in clinical
services, with regard to the treatment of young adults.
No study exclusively investigated the use of KDs for epilepsy
populations with intellectual learning diIiculties. One study
(Sharma 2016) did, however, modify the traditional educational
techniques used to implement the diet, to promote the inclusion of
children with parents who have low levels of literacy and who are
of poor socioeconomic status.
All participants had drug-resistant epilepsy. Eight of the studies
(Kim 2016; KossoI 2007; Lambrechts 2017; McDonald 2018;
Neal 2008; Raju 2011; Sharma 2016; Zare 2017) requested that
participants had trialled two or more antiepileptic drugs while four
studies (Bergqvist 2005; Kverneland 2018; Seo 2007; Sharma 2013
requested that participants had trialled three or more antiepileptic
drugs. One study (El-Rashidy 2013) did not provide information on
how many antiepileptic drugs participants were required to have
previously trialled.
Interventions
There were many variants of KDs used across the 13 included
studies. The interventions used by each study are listed below:
• Bergqvist 2005 compared fasting and gradual-onset 4:1
ketogenic diets (KDs);
• El-Rashidy 2013 compared modified Atkins diet (MAD)
(macronutrients represented as a percentage of total daily
energy – 10% carbohydrate, 60% fat, 30% protein), classic
ketogenic liquid diet (4:1) and usual care (polytherapy);
• Kim 2016 compared MAD (10 g carbohydrate per day for
first month followed by increase to maximum of 10% total
energy requirements, with additional calorie restriction to 75%
recommended daily intake) and classic KD (4:1 ratio);
• KossoI 2007 compared 10 g daily carbohydrate limit MAD and
20 g daily carbohydrate limit MAD;
• Kverneland 2018 compared MAD (up to 16 g carbohydrate per
day, excluding fibre) and usual care;
• Lambrechts 2017 compared KD (classic KD and medium-chain
triglyceride (MCT) KD combined to usual care;
• McDonald 2018 compared MAD (20g net carbohydrates per day)
plus KetoCal (one 8 ounce tetra pack per day) during first month,
followed by MAD alone in second month (intervention) to MAD
alone in the first month, followed by MAD plus KetoCal during
second month (control);
• Neal 2008 compared classic KD (4:1) versus MCT KD
(macronutrients as approximate percentage of total energy
requirements; 15% carbohydrate, 10% protein, 30% long-chain
fatty acids, 45% medium-chain triglycerides);
• Raju 2011 compared a 4:1 and a 2.5:1 ratio KD;
• Seo 2007 compared a 4:1 KD and a 3:1 ratio KD;
• Sharma 2013 compared MAD (10 g carbohydrate per day) to a
usual care group;
• Sharma 2016 compared a simplified MAD (sMAD, 10 g
carbohydrate per day) to usual care;
• Zare 2017 compared MAD (15 g carbohydrate; total energy
derived from 4% to 6% carbohydrate, 20% to 30% protein, 60%
to 70% fat) to usual care.
Outcomes
Twelve of the included studies (Bergqvist 2005; Kim 2016; KossoI
2007; Kverneland 2018; Lambrechts 2017; McDonald 2018; Neal
2008; Raju 2011; Seo 2007; Sharma 2013; Sharma 2016; Zare 2017)
reported 50% or greater reduction in seizure frequency. El-Rashidy
2013 instead reported rate change in seizure frequency at three and
six months. All thirteen studies reported data regarding attrition
and adverse eIects. Additional outcomes included: level of ketosis
(Bergqvist 2005; KossoI 2007); quality of life, cost-eIectiveness,
cognitive and behavioural change (Lambrechts 2017), and dietary
adherence (McDonald 2018).
Funding sources
Ten of the included studies confirmed their source of financial
funding support:
• Bergqvist 2005 was supported in part by RRK-23 16074 and
General Clinical Research Center (MO1RR00240), the Nutrition
Center of the Children's Hospital of Philadelphia, P30 HD26979,
and the Catharine Brown Foundation;
• El-Rashidy 2013 received no external funding support beyond
the treating hospital (Children's hospital, Faculty of Medicine,
Ain Shams University);
• Kim 2016 was supported financially by the National Research
Foundation of Korea (NRF) funded by the Ministry of Education,
Science and Technology;
• Lambrechts 2017 was supported financially by the Netherlands
Organisation for Health Research and Development;
• McDonald 2018 was supported financially by Nutricia North
America;
• Neal 2008 was supported financially by HSA, Smiths Charity,
Scientific Hospital Supplies, and the Milk Development Council.
University College London Institute of Child Health received
funding as a National Institute for Health and Research
Specialist Biomedical Research Centre;
• Seo 2007 was financially supported by Yonsei University
Research Fund of 2003;
• In the study by Sharma 2013, the lead author (Sharma) was
financially supported as a Senior Research Associate in the
“Scientists pool scheme” of the Council for Scientific and
Industrial Research (CSIR), Government. of India, for this study;
• Sharma 2016 was supported financially by the Indian Council of
Medical Research (ICMR);
• Zare 2017 was supported by the Plastic Surgery Research Centre,
Isfahan University of Medical Sciences, Isfahan.
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Two studies (Kverneland 2018; Raju 2011) confirmed that they
received no financial support, while one study did not state any
information regarding funding (KossoI 2007).
Excluded studies
We excluded one additional study at full-text review in the current
update as we suspected that the study was not randomised
(NCT03183076).
Previous editions of this review excluded seven studies; three were
not RCTs (Freeman 1999; Hemingway 2001; Smith 2011), one study
was successfully blinded aDer fasting (by administration of glucose
or saccharin), however, was only for 12 days and ketosis was not
completely eliminated in the glucose arm (Freeman 2009), one
study solely included infantile spasms (Dressler 2015), one study
was available as an abstract only, we were unable to obtain any
further data (Singh 2015), and one study was successfully blinded
aDer fasting (by administration of saccharin or glucose) (Freeman
2009). A summary can be found in Characteristics of excluded
studies table.
Ongoing studies
We identified eight ongoing studies (CTRI/2015/07/006048;
CTRI/2017/12/010898; NCT03764956; NCT03464487; NCT03807141;
Hulshof 2017; NCT02708030; Titre-Johnson 2017 (3 publications
from one study). We will revisit these studies in future review
updates (see Characteristics of ongoing studies).
Risk of bias in included studies
There were 13 RCTs that generated 17 publications reviewing the
use of KDs, all of which were appropriate for analysis of bias. For
further details please refer to Characteristics of included studies
table and Figure 2; Figure 3.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias):
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
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Bergqvist 2005 + + - - ? ? +
El-Rashidy 2013 ? ? - - - ? -
Kim 2016 + + - - ? ? -
Kossoff 2007 ? ? - - ? + +
Kverneland 2018 + + - - ? + -
Lambrechts 2017 + ? - - + + -
McDonald 2018 + ? - - ? ? -
Neal 2008 + + - - + + +
Raju 2011 + + - - + ? -
Seo 2007 ? ? - - + ? +
Sharma 2013 + + - - + + -
Sharma 2016 + + - - + + +
Zare 2017 + ? - - + ? -
 
Allocation
Five studies used a computer-generated method of random
sequence generation (Kim 2016; McDonald 2018; Neal 2008; Raju
2011; Sharma 2013). We therefore awarded the five studies low
risk of selection bias with regard to random sequence generation.
One of these studies used a computer programme to allocate
participants to treatment groups (Neal 2008), whilst another three
studies used opaque sealed envelopes (Raju 2011; Sharma 2013;
Sharma 2016). Kim 2016 meanwhile used independent medical
personnel who were blinded to participants' identity to allocate
participants to treatment groups. We hence judged that all five
studies were at low risk of bias for both random sequence
generation and allocation concealment (Kim 2016; Neal 2008; Raju
2011; Sharma 2013; Sharma 2016). In contrast, McDonald 2018 did
not provide details regarding allocation concealment. We therefore
judged that this study was at unclear risk of selection bias due to
allocation concealment.
One study used a permuted block randomisation method
(Bergqvist 2005), whereby the size of blocks was also randomised.
This method ensured that the pattern of randomisation could not
be predicted, thereby adequately concealing treatment allocation.
Another study also used a permuted block randomisation method
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but with opaque sealed envelopes for allocation concealment
(Sharma 2016). One study used a manual random allocation
sequence which was undertaken by personnel exclusive of the
study team (Kverneland 2018). We thus deemed all three of
these studies to be at low risk of selection bias for both random
sequence generation and allocation concealment (Bergqvist 2005;
Kverneland 2018; Sharma 2016).
The method of sequence generation and allocation concealment
was unclear in three studies (El-Rashidy 2013; KossoI 2007; Seo
2007). No clear details regarding methods for either random
sequence generation or allocation concealment were provided for
any of the three studies. Conversely, Lambrechts 2017 and Zare
2017 both provided methods for random sequence generation
(ALEA clinical online randomisation and a random number table,
respectively) but did not provide any details for allocation
concealment. As a result, we judged that the two studies were at
low risk of selection bias from random sequence generation but
unclear risk of selection bias due to allocation concealment.
Blinding
We rated all 13 studies to be at high risk of performance bias
and detection bias (Bergqvist 2005; El-Rashidy 2013; Kim 2016;
KossoI 2007; Kverneland 2018; Lambrechts 2017; McDonald 2018;
Neal 2008; Raju 2011; Seo 2007; Sharma 2013; Sharma 2016; Zare
2017). Six studies stated they were open-label studies and therefore
featured no blinding (KossoI 2007; Neal 2008; Raju 2011; Sharma
2013; Sharma 2016; Zare 2017), whereas the other seven studies
provided no information regarding blinding of either participants
or outcome assessment (Bergqvist 2005; El-Rashidy 2013; Kim
2016; Kverneland 2018; Lambrechts 2017; McDonald 2018; Seo
2007). Due to the design of such studies, we judged that blinding
of participants and study personnel was very unlikely to have
occurred. We thus assessed these studies to be at high risk of
bias for both blinding domains. Kim 2016 specified that blinded
independent study personnel were responsible for participant
randomisation and allocation, however, it was unclear if outcome
assessors and participants were blinded. We therefore again
assumed that the study was unblinded and awarded high risk for
both performance and detection bias.
Incomplete outcome data
Two studies reported comparable withdrawal rates across the
groups but did not complete an intention-to-treat (ITT) analysis
(Bergqvist 2005; KossoI 2007). Three studies reported comparable
withdrawal rates across the groups but it was unclear if an ITT
analysis was completed (Kim 2016; Kverneland 2018; McDonald
2018). We hence judged that the five studies were at unclear risk of
attrition bias.
Five separate studies also reported comparable withdrawal rates
across the groups and completed an ITT analysis (Lambrechts 2017;
Raju 2011; Seo 2007; Sharma 2013; Sharma 2016). Two studies
reported greater withdrawal from one group, but carried out an ITT
analysis (Neal 2008; Zare 2017). We rated these seven studies to be
at low risk of attrition bias.
One study reported uneven dropout rates across the groups and did
not complete an ITT analysis (El-Rashidy 2013). We rated this study
at high risk of attrition bias.
Selective reporting
Two study protocols had been published and were available
for review (Lambrechts 2017; Sharma 2013). We contacted the
remaining authors of all included studies to request protocols.
Four study authors provided the protocol for the included studies
(KossoI 2007; Kverneland 2018; Neal 2008; Sharma 2016). On
reviewing the outcomes, there was no evidence to suggest selective
reporting for any of these six studies. Therefore, we rated these
studies at low risk of reporting bias. Protocols for the remaining
seven studies were unavailable and we rated these studies at
unclear risk of selection bias (Bergqvist 2005; El-Rashidy 2013; Kim
2016; McDonald 2018; Raju 2011; Seo 2007; Zare 2017).
Other potential sources of bias
One study reported three participants in one intervention group
to have other conditions; two had been diagnosed with infantile
spasms and one with myoclonic encephalopathy (El-Rashidy 2013).
A high level of comorbidity among all groups was reported in one
study, and although the groups were comparable within this study,
bias may be introduced when evaluating in a meta-analysis (Raju
2011).
One study excluded children where motivational issues within
the family had been identified, due to possible impacts upon
compliance rates (Sharma 2013). Similarly, another study included
only those who were motivated and capable of adhering to the diet
(Kverneland 2018).
An energy restriction of 75% of recommended daily intake was
introduced to the MAD group and not to the classical KD group in
another study (Kim 2016). This could potentially enhance ketosis in
the MAD group to the disadvantage of the classical KD group. In the
same study, the significant diIerence noted in seizure reduction in
the children under two years of age in favour of the classical KD, was
likely to be underpowered due to subanalysis.
One study contributed several potential sources of bias
(Lambrechts 2017). Participants with severe motivational and
behavioural diIiculties were excluded, despite the study assessing
the eIects of KD on these outcomes. DiIerences were noted in
baseline mood and behaviour scores, gender balance and baseline
seizure frequency, however significance values were not presented
by the authors to fully assess this. The study was underpowered to
assess quality of life; quality of life was assessed were assessed at
four months by calculating quality-adjusted life years (QALYs) which
may be too premature to assess changes in quality of life, and at the
start of the study no suitable quality of life instrument was available
for utility measures in children aged 0 to 18 years, resulting in
some extrapolation from adult tariIs. As the control group received
KD aDer four months, control data were extrapolated from four
months to 16 months outcomes; although this may have been
due to ethical rationale. The KD group also report significantly
greater gastrointestinal side eIects at baseline compared to the
control group (P < 0.05), which could negatively impact the dietary
intervention.
One study reported numerical errors within the text of the article
in comparison to the tables and did not report a power calculation
(Zare 2017). Low levels of urinary ketosis were reported (1.75 +/-
0.28 mmol/L) which could aIect seizure outcomes.
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One study was underpowered as recruitment was discontinued
aDer six years due to poor uptake, recruiting 75 participants from a
target of 92 (Kverneland 2018). The intervention group in this study
was also dominated by female participants compared to the usual
care group and baseline imbalances regarding types of epilepsy
were present.
One study reported significant diIerences in baseline weight, body
mass index (BMI) and habitually lower energy intake between usual
care and KD groups (McDonald 2018).
We rated these studies at high risk of bias.
A subjective, non-validated tool was used to assess alertness,
speech, sleeping, social and behavioural changes in one study
(Sharma 2016). However, as these measures were assessed using
non-validated tools, we did not include them in this review, and
they therefore had low impact upon bias.
We did not identify any other sources of bias in four studies
(Bergqvist 2005; KossoI 2007; Neal 2008; Seo 2007).
E8ects of interventions
See: Summary of findings 1 Ketogenic diet (KD) compared to
usual care for children with drug-resistant epilepsy; Summary of
findings 2 Ketogenic diet (KD) compared to usual care for adults
with drug-resistant epilepsy; Summary of findings 3 Ketogenic
diets (KDs) compared with other KDs for children with drug-
resistant epilepsy; Summary of findings 4 Ketogenic diets (KDs)
compared with other KDs for adults with drug-resistant epilepsy
All outcomes are presented in: Summary of findings 1, Summary of
findings 2, Summary of findings 3, and Summary of findings 4. The
results for all outcomes are described in more detail below.
Ketogenic diet (KD) versus usual care for children
Seizure freedom (100% reduction in seizure frequency)
In children, four studies (n = 385) reported results for a KD
intervention compared to a usual care group.
• Neal 2008 reported one participant out of 73 (1%) to be seizure
free aDer three months of following a KD (classic KD and
medium-chain triglyceride (MCT)).
• Lambrechts 2017 reported 10% (3/29) of participants in the KD
group to be seizure free at four months, compared to 7% (2/28)
of the usual care group. These values remain unchanged when
reported at 16 months.
• Sharma 2013 reported 10% (5/50) of participants in the modified
Atkins diet (MAD) group to be seizure free at three months,
compared to none in the usual care group.
• Following a simplified MAD (sMAD), Sharma 2016 reported 15%
(6/41) of participants became seizure free, compared to 5%
(2/40) in the usual care group; this result was not significant (P
= 0.26).
Meta-analysis of the above studies favoured the use of KDs
compared to usual care (risk ratio (RR) 3.16, 95% confidence
interval (CI) 1.20 to 8.35; P = 0.02; very low-certainty evidence;
Analysis 1.1). Specifically, the RR calculated indicates that children
randomised to KDs were three times more likely to attain seizure
freedom compared to children randomised to usual care.
50% or greater reduction in seizure frequency (seizure
reduction)
In children, four studies (n = 385) compared KD intervention to a
usual care group.
• Neal 2008 reported 38% (28/73) of participants had greater than
50% seizure reduction aDer three months in the KD (classic and
MCT) group compared to 6% (4/72) of participants in the usual
care group (P < 0.001).
• Lambrechts 2017 stated 34% (10/29) in the KD group compared
to 7% (2/28) in the usual care group experienced greater than
50% seizure reduction at four months. ADer 16 months, seizure
reduction (of greater than 50%) had reduced from 39% to
21% (6/29) in the KD group and 7% (2/28) of the usual care
group. Lambrechts 2017 presented significance values as overall
responders (seizure reduction and seizure freedom combined).
For the KD group 50% (13/26) of participants responded to KD
and 18% (4/22) in the usual care group, illustrating significant
response at four months for the KD group compared to usual
care (P < 0.05).
• When comparing MAD to a usual care group, Sharma 2013
reported significantly higher results in the MAD group (52%) to
usual care (11.5%, P = 0.001), when comparing greater than 50%
seizure reduction at three months.
• Using a sMAD, Sharma 2016 later supported these results,
reporting 56% (23/41) of participants in the sMAD group
experienced greater than 50% seizure reduction compared with
8% (3/40) in the usual care group (P < 0.001).
Meta-analysis of the above studies favoured the use of KDs
compared to usual care for seizure reduction greater than or equal
to 50% (RR 5.80, 95% CI 3.48 to 9.65; P < 0.001; low-certainty
evidence; Analysis 1.3; Figure 4). The RR predicts that children who
receive KDs are nearly six times more likely to attain a 50% or
greater reduction in seizure frequency than children who receive
usual care.
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Adverse e(ects
In children, five studies (n = 425) reported adverse eIects for the
comparison KD versus usual care.
The most frequent adverse eIects reported by participants in
dietary intervention groups were: vomiting, constipation and
diarrhoea. These adverse eIects were also commonly reported by
participants in the usual care groups.
Other less common adverse eIects reported included:
dysphagia, lethargy, lower respiratory tract infection,
hyperammonaemic encephalopathy, weight loss, nausea,
infections (pneumonia, sepsis), acute pancreatitis, decrease in
bone matrix density, gallstones, fatty liver, nephrocalcinosis,
hypercholesterolaemia, status epilepticus, acidosis, dehydration,
tachycardia, hypoglycaemia, hunger, abdominal pain, clinically
relevant reduction in height, hypercalcinaemia and renal stones.
Cognition and behaviour
In children, Lambrechts 2017 (n = 57) was the only study to
investigate the eIect of KDs upon cognition and behaviour,
reporting participants in the KD group to be more active (P = 0.005),
more productive (P = 0.039) and less anxious (P = 0.049) aDer
four months, compared to the usual care group (very low-certainty
evidence).
Quality of life
Similarly, Lambrechts 2017 (n = 57) was the only study to investigate
the eIect of KDs on quality of life. The authors reported no
significant diIerence in quality-adjusted life years (QALYs) between
the KD group and the usual care group at four or 16 months (P value
not reported; very low-certainty evidence).
Attrition rate
In children, five studies (n = 425) reported results for a KD
intervention compared to a usual care group.
The proportion of children withdrawing from treatment in the KD
group ranged from 8% to 38% compared to 2.5% to 32% in the usual
care groups. Meta-analysis data indicated study retention to favour
neither KD or usual care groups in children (RR 1.08, 95% CI 0.74 to
1.57; P = 0.71; low-certainty evidence; Analysis 1.5).
Ketogenic diet versus usual care for adults
Seizure freedom (100% reduction in seizure frequency)
In adults, two studies (n = 141) reported results for a KD intervention
compared to a usual care group.
• Kverneland 2018 reported 0% seizure freedom in both MAD and
the usual care group.
• Zare 2017 reported 0% seizure freedom in both the MAD and the
usual care group.
The meta-analysis for seizure freedom in adults was unable to
estimate an eIect size due to no events being reported (very low-
certainty evidence; Analysis 1.2).
50% or greater reduction in seizure frequency (seizure
reduction)
In adults, two studies (n = 141) compared KD intervention to a usual
care group.
• Kverneland 2018 reported 8% (3/37) in the MAD group and 5%
(2/38) in the usual care group to experience a greater than 50%
reduction in seizures at three months (P = 0.65).
• Zare 2017 reported 35% (12/34) in the MAD group and 0% (0/32)
in the usual care group had greater than 50% reduction in
seizures at two months (P = 0.001).
In adults, meta-analysis data illustrated the eIect of KDs in
reducing seizure frequency to be unclear. Although a very large
eIect size was calculated (RR 5.03, 95% CI 0.26 to 97.68; very low-
certainty evidence; Analysis 1.4; Figure 5), the diIerence between
treatment groups (KD versus usual care) was not statistically
significant (P = 0.29). Notably, the two studies each predicted very
diIerent eIect sizes and this is reflected by the I2 value (I2 = 70%)
which indicates heterogeneity.
 
Ketogenic diets for drug-resistant epilepsy (Review)









Cochrane Database of Systematic Reviews
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Adverse e(ects
In adults, two studies (n = 141) compared KD intervention to a usual
care group.
Adults receiving KD most commonly reported: vomiting,
constipation and diarrhoea. One study reported a significant
reduction in body mass index (BMI), as well as an increase in
cholesterol in the MAD group, whilst the other study reported
significant weight loss. Other adverse eIects included: anorexia,
lethargy, lower respiratory tract infections and hyperammonaemic
encephalopathy.
Cognition and behaviour
In adults, no studies reported this outcome for a KD intervention
compared to a usual care group.
Quality of life
In adults, no studies reported this outcome for a KD intervention
compared to a usual care group.
Attrition rate
In adults, two studies (n = 141) compared a KD intervention to a
usual care group.
The proportion of adults withdrawing from treatment in the MAD
group was 35% in both studies compared to a withdrawal rate of
0% to 16% in the usual care groups. Meta-analysis of data for adults
indicated that retention favoured the usual care groups, however,
the eIect was not statistically significant (RR 5.38, 95% CI 0.42 to
69.53; P = 0.20; very low-certainty evidence; Analysis 1.6).
Ketogenic diet versus ketogenic diet for children
Seizure freedom (100% reduction in seizure frequency)
In children, five studies (n = 286) compared diIerent KD
interventions (very low-certainty evidence).
• Raju 2011 reported 26% (5/19) of participants following a 4:1 KD
and 21% (4/19) of participants following a 2.5:1 KD to be seizure
free at three months.
• Seo 2007 found a greater response rate to both ratios of the
KD, reporting 55% (22/40) of participants to be seizure free aDer
following a 4:1 KD for three months compared to 35% (11/36) of
participants following a 3:1 KD.
• When comparing a fasting-onset and a gradual-onset KD,
Bergqvist 2005 stated 21% (5/24) of participants of both fasting-
onset and gradual-onset KD groups were seizure free at three
months.
• When investigating the eIects of MAD on seizure freedom, Kim
2016 reported a significant diIerence between classic KD (33%;
17/51 participants) and MAD (25%; 13/53 participants) aDer
three months (P = 0.374), but no diIerence aDer six months.
When results were divided into subsequent age categories (1 to
2 years, 2 to < 6 years and 6 to 18 years) more children under
the age of two years experienced seizure freedom following
the classic KD (9/17) compared to the MAD (4/20) (P = 0.047).
However, this result is likely to be statistically underpowered.
• KossoI 2007 reported 10% (2/20) of participants to be seizure
free by six months. However, the intervention group (10 g or 20
g carbohydrate per day via MAD) was not stated.
Due to heterogeneity of both interventions and methodology, we
could not conduct a meta-analysis for studies comparing diIerent
KD interventions in children.
50% or greater reduction in seizure frequency (seizure
reduction)
In children, five studies (n = 286) compared diIerent KD
interventions (very low-certainty evidence).
• Raju 2011 found the number of participants with greater than
50% seizure reduction aDer three months to be 58% (11/19) in
the 4:1 KD group and 63% (12/19) in the 2.5:1 KD group; however,
there was no significant diIerence.
• Seo 2007 stated 85% (34/40) of participants following a 4:1 KD
and 72.2% (26/36) of participants following a 3:1 KD to have
greater than 50% seizure reduction aDer three months. Seo 2007
reported that antiepileptic eIicacy was significantly greater in
the 4:1 KD group than the 3:1 KD group (P = 0.041), but it was
unclear as to whether this referred to seizure reduction, seizure
freedom or both.
• When comparing fasting-onset and gradual-onset KD, Bergqvist
2005 found 58% (14/24) of participants in the fasting-onset KD
and 67% (16/24) of participants in the gradual-onset KD group
to have greater than 50% seizure reduction at three months.
• When comparing classic KD to MAD, Kim 2016 reported 43%
(22/51) of participants in the classic KD and 42% (22/53) in
the MAD group (P = 0.527) reporting greater than 50% seizure
reduction. At six months, 39% (20/51) of participants in the
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classic KD group and 36% of the MAD group reported greater
than 50% seizure reduction (P = 0.321), therefore no diIerence
was observed between the groups.
• When comparing proportions of carbohydrate in the MAD group,
KossoI 2007 reported a significant diIerence (P = 0.03) in seizure
reduction aDer three months, between 10 g carbohydrate MAD
and 20 g carbohydrate MAD, with 60% (6/10) of participants
in the 10 g carbohydrate/day group having greater than 50%
seizure reduction compared to 10% (1/10) of participants in the
20 g carbohydrate/day group.
Due to heterogeneity of both interventions and methodology, we
could not conduct a meta-analysis for studies comparing diIerent
KD interventions in children.
Adverse e(ects
In children, five studies (n = 286) compared diIerent KD
interventions for adverse eIects.
The most frequent adverse eIects reported by children were:
vomiting, constipation and diarrhoea. Two studies reported
weight loss, with one study stating that weight loss and
gastrointestinal disturbances were more frequently reported with
4:1 KD versus 3:1 KD. One study reported a significantly high
incidence rate for hypercalcuria amongst children receiving
classic KD compared to MAD at three months. There was no
significant diIerence in weight loss between treatment groups
given 20 mg/d versus 10 mg/d carbohydrates. Other adverse
eIects reported included dysphagia, lethargy, lower respiratory
tract infection, hyperammonaemic encephalopathy, nausea,
infections (pneumonia, sepsis), acute pancreatitis, decrease in
bone matrix density, gallstones, fatty liver, nephrocalcinosis,
hypercholesterolaemia, status epilepticus, acidosis, dehydration,
tachycardia, hypoglycaemia, hunger, abdominal pain, clinically
relevant reduction in height, hypercalcinaemia and renal stones.
Cognition and behaviour
No studies reported this outcome.
Quality of life
No studies reported this outcome.
Attrition rate
In children, five studies (286 participants) compared treatment
withdrawal across diIerent KD interventions. The proportion of
children withdrawing from KD groups were: 8% attrition for
gradual-onset KD; 16% attrition on 2:5:1 KD and on 4:1 KD; 17%
attrition on fasting-onset KD and on the 3:1 KD; 32% attrition on
MAD; and 33% attrition on the classic KD.
Ketogenic diet versus ketogenic diet for adults
Seizure freedom (100% reduction in seizure frequency)
In adults, one study (McDonald 2018) measured seizure freedom
when comparing diIerent KD interventions. No adult participants
in either treatment groups, MAD plus KetoCal in month one
(intervention) or MAD plus KetoCal in month two (control),
achieved seizure freedom (very low-certainty evidence).
50% or greater reduction in seizure frequency (seizure
reduction)
In adults, one study (n = 80) compared diIerent KD interventions
(very low-certainty evidence).
• When comparing MAD with KetoCal for month one
(intervention), to MAD with KetoCal during month two (control),
McDonald 2018 reported 35% (17/40) of the intervention group
and 33% (13/40) of the control group to be experiencing greater
than 50% reduction in seizures. At two months, 33% (13/40) of
the intervention group and 25% (10/40) of the control group
were experiencing greater than 50% reduction in seizures. ADer
six months, 25% (10/40) of the intervention group and 25%
(10/40) of the control group were experiencing greater than 50%
seizure reduction.
Adverse e(ects
In adults, one study (n = 80) compared diIerent KD interventions.
Constipation was reported more frequently by adults in the
MAD plus KetoCal group (17.5%) compared to the MAD only
treatment group (5%). Diarrhoea and increase/change in seizure
pattern/semiology were also commonly reported (17.5% to
20% of participants). Other less commonly reported adverse
eIects included: abdominal pain, headache, irregular menses,
halitosis, somnolence, nephrolithiasis, kidney infection, nausea,
easy bruising, vaginal odour and brittle hair/nails.
Cognition and behaviour
No studies reported this outcome.
Quality of life
No studies reported this outcome.
Attrition rate
In adults, one study (80 participants) compared attrition across
diIerent KD interventions. Specifically, 12.5% of adults withdrew
from the intervention group (MAD plus KetoCal month 1) compared
to 32.5% from the control group (MAD plus KetoCal month 2).
D I S C U S S I O N
Summary of main results
The present update identified two additional randomised
controlled trials (RCTs) and, therefore, this review includes 13 RCTs;
three of which investigated the eIect of MAD in adults with epilepsy
(Kverneland 2018; McDonald 2018; Zare 2017).
In relation to children, meta-analysis favoured the use of ketogenic
diets (KDs) compared to usual care in promoting seizure freedom
(risk ratio (RR) 3.16, 95% confidence interval (CI) 1.20 to 8.35; P =
0.02) and seizure reduction ≥ 50% of baseline (RR 5.80, 95% CI 3.48
to 9.65; P = 0.001). In children, reported rates of seizure freedom
reached 55% in a 4:1 KD group aDer three months and reported
rates of seizure reduction reached 85% in a 4:1 KD group aDer three
months (Seo 2007). Studies assessing the eIicacy of the modified
Atkins diet (MAD) in children reported seizure freedom rates of up
to 25% and seizure reduction rates of up to 60%.
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Interestingly, Bergqvist 2005 found no significant diIerence
between the fasting-onset and gradual-onset KD for rates of seizure
freedom in children with epilepsy and reported a greater rate of
seizure reduction in the gradual-onset KD group.
One study reported a significant diIerence between classic KD and
the less restrictive MAD aDer three months (P = 0.374) in terms of
seizure reduction, but no diIerence aDer six months (Kim 2016).
Of further interest, this study is the first RCT to report on KDs in
children under two years of age in relation to seizure freedom,
suggesting classical KD may be more eIective than MAD (P = 0.047).
However, this result is likely to be statistically underpowered and
requires further investigation.
In adults, the eIect of the MAD is less clear, with no participants
experiencing seizure freedom (Kverneland 2018; Zare 2017), and
mixed eIects noted in seizure reduction of 50% or greater (RR
5.03, 95% CI 0.26 to 97.68; P = 0.29). The first RCT for MAD in
adults reported seizure reduction rates of 35% at two months (Zare
2017), which is lower than that of children, but remains statistically
significant compared to the usual care group (P = 0.001). However,
a more recent study has shown less promising results with 8% of
participants experiencing 50% or more seizure reduction compared
to usual care (Kverneland 2018). McDonald 2018 found KetoCal to
be tolerable by adults for a one-month period, reporting seizure
reduction rates of up to 55% during this time.
Adverse eIects were fairly consistent across diIerent dietary
interventions. The most commonly reported adverse eIects were
gastrointestinal syndromes. Two of the adult studies reported
derangements in lipid profiles (McDonald 2018; Zare 2017),
however the clinical significance and long-term eIect of this
requires further investigation. It was common that adverse eIects
were the reason for participants dropping out of studies. Other
reasons for drop out included lack of eIicacy, non-compliance and
non-acceptance of the diet.
Although there was some evidence for greater antiepileptic eIicacy
for a 4:1 KD over lower ratios, the 4:1 KD was associated with more
adverse eIects in the majority of studies.
Only one study assessed the eIect of dietary interventions on
quality of life and found no diIerence between quality-adjusted
life years (QALYs) when comparing KD to usual care (Lambrechts
2017). This study is also the only study to report upon cognitive
or behavioural functioning, suggesting the KD group to be more
active, more productive and less anxious. However, given the
limitations of the study, further evidence investigating the eIects
of KDs on quality of life and cognitive and behavioural functioning
would be beneficial before drawing conclusions.
Overall completeness and applicability of evidence
The present review identified 13 RCTs with a total sample size of
932 people with epilepsy, three of which were in adult populations.
The eIect of KDs for adults remains unclear, highlighting the need
for further research in this field. Additionally, more studies that
investigate the use of KDs in children are required to expand
and improve the certainty of the evidence available for paediatric
populations.
We also require more studies that evaluate the eIects of KDs on
cognitive and behavioural outcome and on quality of life. Currently,
only one study has assessed cognitive and behavioral outcomes in
a RCT of KD, and only one other separate study has reported quality
of life. The evidence we have acquired is therefore inadequate to
inform clinical practice about the eIects of KDs on these outcomes.
The studies in both adults and children were all of short duration,
with none longer than 16 months. The evidence therefore is
restricted to the short-term eIects of KDs and is unable to provide
information on the long-term eIicacy or tolerability of KDs.
Notably, meta-analysis for all planned comparisons was not
possible due to the clinical and methodological heterogeneity
observed and the limited data available. Thus, meta-analysis was
restricted to studies comparing KDs with a usual care group. For
the purposes of this meta-analysis, we considered it appropriate
to group all variations of the KD together as a single ketogenic
intervention. The eIects of the intervention were then compared
against the continuation of usual care without dietary intervention.
Similarly, we did not feel that it was appropriate to combine the
data from adults and children into a single meta-analysis, due to the
obvious heterogeneity between the treatment eIects estimated.
Certainty of the evidence
The certainty of evidence judgements for all GRADE-assessed
outcomes for the four comparisons are displayed in Summary of
findings 1, Summary of findings 2, Summary of findings 3, and
Summary of findings 4.
We GRADE-assessed the majority of outcomes as being derived
from very low-certainty evidence. Consequently, this means that
we are very uncertain whether the findings that we have reported
for these outcomes are accurate of the true eIect; the true eIect
could likely be substantially diIerent from that described in this
review. We rated the evidence for three outcomes as low certainty,
meaning that we are uncertain about the accuracy of the eIect
estimate we have provided (seizure reduction, adverse eIects and
attrition for 'Ketogenic diet compared to usual care for children
with drug-resistant epilepsy'; (Summary of findings 1)). There is a
possibility that the eIect estimate could be considerably diIerent
from the true eIect, but we are unsure.
We downgraded all outcomes across the four comparisons once
for risk of bias aDer we detected significant risk of bias across all
included studies. This was largely due to a lack of blinding and
unclear methodological reporting. There was also an issue with
missing data for several of the included studies. The studies either
did not complete intention-to-treat (ITT) analysis or did not clarify
whether or not it was used.
Another common issue that impacted the majority of outcomes
was imprecision. Specifically, there were limited data available,
regarding KDs, with a restricted number of events reported for
many outcomes. Consequently, the suggested optimal information
size was not satisfied on most occasions. This thus implied that
the analysis may not have been adequately powered. We also
found it necessary to downgrade for imprecision due to the data
synthesis conducted. Certain outcomes, such as cognition and
behaviour, and quality of life, required a narrative synthesis due
to the heterogenous approaches used to assess them. A narrative
synthesis does not estimate a weighted eIect size, and therefore is
not an accurate representation of the true eIect. This hence results
in a downgrading for imprecision. With regard to dichotomous
outcomes, such as seizure freedom for the comparison 'Ketogenic
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diet compared with other ketogenic diets for children with drug-
resistant epilepsy' (Summary of findings 3), unfortunately, due to
the heterogeneity in the interventions of the included studies, we
judged that it was inappropriate to combine data into a meta-
analysis. Instead, we performed a narrative synthesis. This again
contributed to a downgrading of evidence.
The heterogeneity observed in data sets also negatively impacted
another GRADE-assessed domain, inconsistency. Specifically, two
outcomes, seizure reduction and treatment withdrawal for the
comparison 'Ketogenic diet compared to usual care for adults
with drug-resistant epilepsy' (Summary of findings 2), displayed
significant statistical heterogeneity, and therefore we downgraded
once for inconsistency. It was necessary to downgrade the certainty
of evidence for multiple outcomes for the comparisons, 'Ketogenic
diets compared with other ketogenic diets for children with
drug-resistant epilepsy' (Summary of findings 3) and 'Ketogenic
diets compared with other ketogenic diets for adults with drug-
resistant epilepsy' (Summary of findings 4), due to the observed
heterogeneity in interventions used.
Overall, the certainty of evidence for this review has been limited
by the associated risk of bias, the observed heterogeneity between
studies, and the low number of participants recruited to study
populations.
Potential biases in the review process
Despite the thorough search strategies, we cannot be certain that
we identified and included all relevant data in this review. Should
we identify further data following publication of this review, we will
incorporate it into subsequent updates.
There was limited information about the included studies, in
particular study protocols were unavailable for the majority of
included studies, therefore decisions within the 'Risk of bias'
assessment were oDen based on insuIicient information, resulting
in a number of unclear 'Risk of bias' judgements.
We also encountered issues with young adults being incorporated
into both the adult and child study populations for the trials that
we included in this review. One adult study included participants
as young as 16 years old (Kverneland 2018), whilst three of the
child studies included participants up to the age of 18 years old
(Kim 2016; KossoI 2007; Lambrechts 2017). Consequently, data
from people with drug-resistant epilepsy, aged 16 to 18 years old,
has been considered and analysed in both of our comparisons.
Although this is not useful to young adults with drug-resistant
epilepsy and their clinicians who are deciding whether a KD will
be beneficial, it is reflective of current clinical practice, whereby
the age for transition from paediatric to adult health services is
variable.
Agreements and disagreements with other studies or
reviews
We found, and excluded, two prospective, but not RCTs
investigating the eIect of KD in an adult population (KossoI
2008; Moesk 2009). KossoI 2008 investigated the eIects of a
MAD (30 participants), while Moesk 2009 used a classic 4:1 KD
(9 participants). Dropout rates varied between 30% and 77%,
reportedly due to feelings of hunger, dietary restrictions and lack
of eIicacy. Moesk 2009 reported that both of the participants who
completed the study had greater than 50% seizure reduction by
three months, while KossoI 2008 reported that 47% of participants
had experienced this level of seizure reduction. Both studies
reported an increase in cholesterol levels. The eIicacy findings
of KossoI 2008 were similar to those of the included paediatric
RCTs discussed above, but greater than what is observed in
studies comparing KDs to usual care (Kverneland 2018; Zare
2017). However, attrition rates experienced by Moesk 2009 were
considerably higher than the RCTs conducted on children or the
adult RCTs, which may suggest tolerability of a 4:1 KD or lack
of eIicacy to be problematic in the adult population. We note
however, that the adult RCTs included in this review are of short
duration, three months or less.
Further prospective studies with children reported similar levels
of seizure reduction to those of the included RCTs (Coppola 2002;
Hosain 2005). Hosain 2005 administered a KD via gastrostomy tubes
and reported compliance rates of 100% (12 children), likely due to
the method of delivery.
Retrospective studies found 35% and 58% of children to have
greater than 50% seizure reduction following six months of KD
(DiMario 2002; Kang 2005). However, given the time scale, direct
comparisons of results are diIicult. Adverse eIects in both studies
were mild and self-limited. Kang 2005 reported a 32% dropout rate,
which is slightly greater than the included RCTs, reportedly due to
complications and dietary intolerances. However, four participants
were also reported to have died during the study, three due to
lipoid pneumonia and infectious illnesses that occurred within
three months of starting a KD.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The collective evidence presented in this review suggests an eIect
for ketogenic diets (KDs) for epilepsy in children. The limited
number of studies in both adults and children, small sample sizes
and generally short-term follow-up, however, resulted in low- to
very low-certainty evidence for the majority of outcomes.
All studies comparing all KD variations reported adverse eIects,
from short-term gastrointestinal-related disturbances, to longer-
term complications. The adverse eIects associated with the
modified Atkins diet (MAD) may initially appear lower than the
classic KD, but further studies are required.
Attrition rates remained a problem in all KDs and across all
studies, reasons for this being lack of observed eIicacy and dietary
intolerance.
One study found no significant diIerence in seizure reduction
between gradual-onset and fasting-onset KD, further analysis
would be beneficial to assess cost-eIectiveness. However, further
large-scale studies are required.
The eIect of KDs on quality of life, cognition and behaviour requires
further investigation.
There was a lack of evidence for the use of KDs in adults or infants
with epilepsy, therefore, further research would be of benefit.
Other more palatable but related diets, such as the MAD, may have a
similar eIect on seizure control as classical KD, but this assumption
requires further investigation.
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For people who have medically intractable epilepsy or people who
are not suitable for surgical intervention, KDs remain a valid option,
however, further research is required.
Implications for research
Key areas for research identified by this review are as follows.
• Studies should address quality of life issues and cognitive
changes, using a validated scale.
• Further studies utilising economic modelling (quality-adjusted
life years; QALYs) would be of benefit.
• Consistency in outcomes across RCTs would be beneficial
through a core outcome set, for example it would beneficial
for future RCTs to assess seizure frequency by means of seizure
reduction (greater than 50% reduction in seizures) and seizure
freedom (100% reduction in seizures).
• Although shorter studies (e.g. 6 months) provide useful evidence
for the eIicacy of dietary interventions, it may be useful to
assess the tolerability and adverse eIects of such interventions
in long-term studies that follow participants for over 12 months
or preferably several years.
• Studies of the mechanisms of action could help determine which
specific seizure types or syndromes respond better to the diets.
• Further studies should address other diets, particularly those
that are less restrictive (such as the MAD).
• The present review highlighted a paucity of evidence for the use
of the KD in adults and infants. Therefore, future studies should
investigate the use and potential adverse eIects of KDs in adults
and infants with epilepsy.
• Large-scale RCTs would be of benefit.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Prospective, randomised, single-centre study comparing Fast KD and Grad KD over a 3-month period.
Baseline data of seizure activity was collected 28 days prior to diet initiation.
Participants • 48 children, 24 in each of the 2 arms, aged 1-14 years (mean 5.3, SD 2.7 years), having ≥ 1 seizures per
28 days, tried at least 3 AEDs and a discontinuation of steroidal medication 3 months previous. Study
undertaken in Philadelphia, USA. All generalised and focal seizures included;
• Exclusion criteria: children with metabolic disorders, genetic disorders and known or suspected neu-
rodegenerative disorders. 42% of children included in the study had cerebral palsy.
Bergqvist 2005 
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Interventions Speed of introduction of KD: Fast KD (< 48 hour fast, followed by 4:1 KD with increase in portion size
over 6 days) or Grad KD (gradual increase in KD ratio from 1:1 to 4:1 over 6 days)
Outcomes • Proportion of participants with > 50% seizure reduction in target seizure type;
• Level of ketosis;
• Adverse effects.
Notes • In the first 6 days of the KD trial, 2 participants dropped out, 1 with pancreatitis (Fast KD) and 1 due to
viral gastrointestinal illness (Grad KD). 3 further drop outs occurred in the Fast KD prior to 3 months'
follow-up, 1 due to respiratory distress and 2 due to lack of efficacy. In the Grad KD group, 1 participant
withdrew due to lack of efficacy;
• This study was supported in part by RRK-23 16074 and General Clinical Research Center (MO1R-
R00240), the Nutrition Center of the Children's Hospital of Philadelphia, P30 HD26979, and the
Catharine Brown Foundation.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants stratified by age (1 to 2 years and 2 to 14 years); randomisation in
permuted blocks of random size (2 to 4).
Allocation concealment
(selection bias)
Low risk Randomisation through permuted blocks of random size of groups of 2 or 4





High risk Blinding was not discussed in this paper, but considering the design of the
study, blinding of participants and study personnel does not seem possible.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Blinding was not discussed in this paper, but considering the design of the
study, blinding of outcome assessors does not seem possible.
Incomplete outcome data
(attrition bias)
Unclear risk Similar attrition rate in both groups, numbers too small for statistical analysis.
No ITT analysis completed.
Selective reporting (re-
porting bias)
Unclear risk Protocol unavailable.





Methods Single-centre randomised controlled trial to comparing two different dietary interventions (MAD and
classic KD in form of 4:1 liquid diet) and a control group (AED polytherapy).
Participants • 40 children aged 12-36 months (mean 27.13, SD 6.63) with symptomatic intractable epilepsy. Study
undertaken in Egypt;
• Exclusion criteria: children < 1 year, diagnosed with idiopathic epilepsy or with other systemic chronic
conditions;
El-Rashidy 2013 
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• Two children in the classic group had infantile spasms and one child in the classic group had myoclonic
encephalopathy.
Interventions • Participants were randomised into 1 of 3 groups; MAD (15 participants), KD (10 participants) and con-
trol (polytherapy) (15 participants);
• 4:1 refers to 4 g fat to 1 g of carbohydrate and protein combined.
Outcomes • Reduction in seizure frequency;
• Adverse effects;
• Attrition rate.
Data were collected at 3 and 6 months.
Notes • 2 participants in the MAD group dropped out of the trial as they could not accept the diet and experi-
enced weight loss. From the results, it could be inferred that these participants dropped out between
the 3- and 6-month reviews. 2 participants from the classic KD group dropped out due to intolerance;
however, it was unclear when these participants dropped out;
• No external funding support was received for this study beyond the treating hospital (Children's hos-
pital, Faculty of Medicine, Ain Shams University).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Although the paper stated that participants were 'randomly assigned', there










High risk Blinding was not discussed in this paper, but considering the design of the
study, blinding of participants and study personnel does not seem possible.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Blinding was not discussed in this paper, but considering the design of the
study, blinding of outcome assessors does not seem possible.
Incomplete outcome data
(attrition bias)
High risk Study attrition was reported but ITT analysis was not carried out. Reasons for
drop outs were likely to be related to interventions.
Selective reporting (re-
porting bias)
Unclear risk Emailed author regarding protocol, awaiting response from co-authors. Proto-
col currently unavailable.
Other bias High risk No measure of seizure frequency reported at baseline. 20% of participants in





Methods Prospective, single-centre, randomised trial to compare MAD (75% energy restriction) to classic KD (4:1
ratio). Four week baseline period completed.
Kim 2016 
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Participants • 104 participants aged 1 to 18 years, with drug-resistant epilepsy, experiencing more than 4 seizures
per month, with treatment failure following 2 or more AEDs. Study was conducted in Korea;
• Exclusion criteria: history of previous diet therapy, hyperlipidaemia, renal calculi, any other medical
contraindications for diet therapy;
• Epilepsy syndromes included Lennox-Gastaut syndrome (10 participants in the MAD and 8 partici-
pants in the KD group), West syndrome (8 participants in the MAD and 12 participants in the KD group),
myoclonic astatic epilepsy (1 participant in each group) and Dravet syndrome (2 participants in the
MAD and 4 participants in the KD group).
Interventions • Randomised into 1 of 2 groups; MAD (10 g carbohydrate per day for the first month, followed by in-
crease to 10% of total energy requirements, with energy restriction to 75% of recommended daily in-
take) and classic KD (4:1 ratio) for a 6-month period;
• 4:1 refers to 4 g fat to 1 g of carbohydrate and protein combined. All recruited participants were hos-
pitalised to commence the diet and followed a non-fasted initiation protocol.





Notes • At 3 months 12 participants had discontinued the classic KD; 1 due to inefficacy, 7 due to intolerance
and 4 due to side effects. In the MAD group 6 participants had discontinued diet; 3 due to inefficacy,
2 due to intolerance and 1 due to side effects. By 6 months a further 5 participants discontinued to
classic KD; 1 due to inefficacy, 1 due to intolerance and 3 due to side effects. In the MAD group 11 had
discontinued diet; 3 due to inefficacy, 6 due to intolerance and 2 due to side effects;
• This study was supported financially by the National Research Foundation of Korea (NRF) funded by
the Ministry of Education, Science and Technology.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Stratified permuted block randomisation using statistical software. Minimisa-
tion method used to adjust for age (1 to 2 years, 2 to 6 years, 6 to 18 years).
Allocation concealment
(selection bias)
Low risk Independent medical personnel were responsible for allocating participants to





High risk Blinding was not discussed in this paper, but considering the design of the
study, blinding of participants and study personnel does not seem possible.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Blinding was not discussed in this paper, but considering the design of the
study, blinding of outcome assessors does not seem possible.
Incomplete outcome data
(attrition bias)
Unclear risk Study attrition reported and unclear if ITT analysis carried out.
Selective reporting (re-
porting bias)
Unclear risk Protocol unavailable.
Other bias High risk An energy restriction of 75% of recommended daily intake applied to MAD
group and not classical KD group. Significant difference noted in the children
Kim 2016  (Continued)
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under 2 years of age in favour of the classical KD likely to be underpowered





Methods Prospective, randomised, cross-over controlled trial to compare daily carbohydrate limits of 10 g and
20 g, using the MAD over a 6-month period.
Participants • 20 children, aged 3-18 years with intractable epilepsy, with a prior use of at least 2 AEDs and experi-
encing daily seizures. All seizure types included. Study conducted in Baltimore USA;
• Exclusion criteria: children with prior experience of the diet for > 7 days, hypercholesterolaemia, kid-
ney dysfunction, BMI < 3% for age and children with heart disease;
• Epilepsy syndromes included were idiopathic (15 children), Rett syndrome (2 children), cortical dys-
plasia (2 children) and tuberous sclerosis complex (1 child).
Interventions MAD with randomisation either to 10 g (10 children) or 20 g (10 children) of carbohydrate and cross-
over at 3 months.
Outcomes • Seizure reduction;
• Level of ketosis;
• Tolerability.
Notes • 3 (30%) participants dropped out in the 10 g carbohydrate/day group and 5 (50%) participants in the
20 g carbohydrate/day group by 6 months, no significance was found between the groups (P = 0.33).
Reasons for drop out were not stated;
• Funding support for this study was not stated.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated.
Allocation concealment
(selection bias)





High risk Open-label study meaning participants and personnel were not blinded.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Open-label study meaning outcome assessors were not blinded.
Incomplete outcome data
(attrition bias)
Unclear risk Greater attrition rate in 20 g carbohydrate group but not significant. 3/10 in
10 g carbohydrate and 5/10 in 20 g carbohydrate group did not complete the
study. P = 0.33. No ITT analysis completed.
Selective reporting (re-
porting bias)
Low risk Protocol received. No evidence to suggest selective reporting.
Kosso8 2007 
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Methods Prospective, randomised controlled trial comparing MAD (up to 16 g carbohydrate per day, excluding
fibre) to a usual care over a three-month period.
Participants • 75 adult participants aged 16 years or over, with focal or multifocal epilepsy, at least three countable
seizures per month, tried at least three AEDs, BMI > 18.5kg/m2, motivated and capable of adhering to
the diet, with assistance if required. Participants were referred from across Norway;
• Exclusion criteria: pregnancy, previous use of KD in past 12 months, change of AED treatment, non-
epileptic seizures, status epilepticus in past six months, resective surgery or vagal nerve stimulation
in past 12 months or comorbidities that contraindicate use of the KD.
Interventions MAD (up to 16 g carbohydrate per day, excluding fibre; 37 participants) compared to usual care (38 par-
ticipants) over a three-month period.
Outcomes • Seizure reduction;
• Adverse effects;
• Changes in body weight;
• Changes in selected biomarkers.
Notes • 13 participants dropped out from the treatment arm; 9 did not receive the diet and 4 were lost to
follow-up. In the usual care arm 6 participants dropped out; 3 did not start the treatment period, 1
was excluded as commenced diet during the control period and 2 were lost to follow-up.
• No funding was received for this study.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Manual random allocation sequence.
Allocation concealment
(selection bias)





High risk Blinding was not discussed in this paper, but considering the design of the
study, blinding of participants and study personnel does not seem possible.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Blinding was not discussed in this paper, but considering the design of the
study, blinding of outcome assessors does not seem possible.
Incomplete outcome data
(attrition bias)
Unclear risk Unclear if ITT used.
Selective reporting (re-
porting bias)
Low risk Protocol received. No evidence to suggest selective reporting.
Kverneland 2018 
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Other bias High risk Study discontinued after 6 years due to limited recruitment; initial study pow-






Methods Prospective, single-centre, non-blinded, randomised controlled trial to compare KD (classic KD and
MCT KD) to a control (usual care) group over a 4-month period. Follow-on studies then compared long-
term clinical outcomes at 16 months, cognitive and behavioural impacts and an economic evaluation.
A 4-week baseline period was completed.
Participants • 57 participants aged 1 to 18 years with drug-resistant epilepsy, seizures not adequately controlled
by 2 or more AEDs and surgical remedial causes of epilepsy not viable. Study was conducted in the
Netherlands;
• Exclusion criteria: medical contraindications, behavioural or motivational problems that would pre-
clude compliance;
• Epilepsy syndromes included West syndrome (3 participants in KD group and 2 participants in usual
care group), Lennox-Gastaut syndrome (1 participant in KD group), Doose syndrome (3 participants in
KD group and 2 participants in usual care group), Dravet syndrome (1 participant in KD group), child-
hood absence epilepsy (1 participant in KD group), epilepsy with myoclonic absences (1 participant in
KD group), generalised epilepsies (4 participants in KD group and 6 participants in usual care group)
and localisation-related epilepsies (12 participants in each group).
Interventions Randomised into 1 of 2 groups; KD (classic KD and MCT KD) and control (usual care) for a four-month
period
Outcomes • Seizure reduction;
• Adverse effects;
• Attrition;
• Quality of life;
• Cost-effectiveness;
• Cognitive and behavioural changes.
Notes • 7 participants in the KD group dropped out by 4 months; 1 due to compliance, 1 due to ineffectiveness,
1 due to ineffectiveness combined with adverse effects, 2 due to adverse effects alone, 1 due to change
in seizure pattern and 1 due to withdrawn consent. In the usual care group 9 participants dropped
out, all 9 due to dissatisfaction with randomisation arm. By 16 months, a further 4 participants had
discontinued KD; 2 due to compliance, 1 due to ineffectiveness and 1 due to ineffectiveness combined
with adverse effects. Data at 16 months for the usual care group is not presented as the usual care arm
had no option to commence KD after the initial 4-month treatment period was completed;
• Differences in baseline demographics between groups for gender (18 male in KD group and 9 male in
usual care group), daily seizures (10 participants in KD group and 3 participants in usual care group),
almost daily seizures (5 participants in KD group and 10 participants in usual care group) and etiology
(9 genetic aetiology in KD group and 1 in usual care group; 2 structural aetiology in KD group and 10
structural in usual care group);
• The study was supported financially by the Netherlands Organisation for Health Research and Devel-
opment.
Risk of bias
Bias Authors' judgement Support for judgement
Lambrechts 2017 
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Random sequence genera-
tion (selection bias)
Low risk ALEA, minimisation method of sequence generation.
Allocation concealment
(selection bias)





High risk Blinding was not discussed in this paper, but considering the design of the
study, blinding of participants and study personnel does not seem possible.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Blinding was not discussed in this paper, but considering the design of the
study, blinding of outcome assessors does not seem possible.
Incomplete outcome data
(attrition bias)
Low risk Study attrition reported and ITT analysis carried out.
Selective reporting (re-
porting bias)
Low risk Protocol published. No evidence to suggest selective reporting bias.
Other bias High risk Excluded participants with motivational or behavioural problems. Baseline
differences in mood and behaviour scores, gender balance and seizure fre-
quency (no significance value reported to fully assess extent). Gastrointestinal
problems greater at baseline in KD group compared to usual care (P < 0.05).





Methods Prospective, randomised controlled trial, single-centre, comparing two MAD interventions: 1) MAD plus
KetoCal during first month, followed by MAD alone in second month (intervention) to 2) MAD alone in
the first month, followed by MAD plus KetoCal during second month (control) with MAD consisting of
20 g net carbohydrates per day. The intervention was conducted for two months, with a six-month fol-
low-up period.
Participants • 80 adult participants aged 18 years and over, four quantifiable seizures per month minimum, failed
trial of two or more AEDs. Participants were recruited from Johns Hopkins Hospital, USA;
• Exclusion criteria included: unwillingness to restrict carbohydrate, BMI < 18.5kg/m2, pregnant, history
of kidney disease, hypercholesterolaemia, milk allergy, metabolic or mitochondrial disorder in which
KDs are contraindicated, prior use of MAD for two days or more, use of KetoCal at any time, use of
classical KD in the past year.
Interventions A comparison of two MAD interventions: 1. MAD plus KetoCal during first month, followed by MAD alone
in second month (intervention) to 2. MAD alone in the first month, followed by MAD plus KetoCal during
second month (control) with MAD consisting of 20 g net carbohydrates per day. The intervention was
conducted for two months, with a six-month follow-up period.
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Notes • From the treatment arm, 5 participants dropped out: 1 lost to follow-up; and 4 discontinued the in-
tervention. Four were excluded from the 1-month analysis due to incomplete seizure logs or change
in medication. In the control arm, 13 participants dropped out: 4 elected not to start the control diet;
4 lost to follow-up; and 5 did not adhere to the intervention. Two were excluded from the 1-month
analysis due to lack of seizure log or changes to medication;
• Differences is baseline demographics were noted for mean weight (185.3 +/- 48.5 lbs in the control
group and 162.3 +/- 49.7 lbs in the intervention group; P = 0.039) and mean BMI (30.3 lbs/in2 in control
group; 25.9 lbs/in2 in intervention group; P = 0.007). carbohydrate, BMI <18.5kg/m2;
• This study was supported financially by Nutricia North America.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number allocation.
Allocation concealment
(selection bias)





High risk Blinding was not discussed in this paper, but considering the design of the
study, blinding of participants and study personnel does not seem possible.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Blinding was not discussed in this paper, but considering the design of the
study, blinding of outcome assessors does not seem possible.
Incomplete outcome data
(attrition bias)
Unclear risk Unclear if ITT used in study analysis.
Selective reporting (re-
porting bias)
Unclear risk Protocol unavailable.
Other bias High risk Power calculation based on 85% retention rate (70% retention achieved in





Methods Prospective, randomised, non-blinded, controlled trial comparing KD (classic (4:1) and MCT combined)
to usual care over a 3-month period, with a follow-on study then compared classic KD versus MCT KD
over a 12-month period. 4-week seizure baseline completed.
Participants • 145 children (aged 2-16 years), with daily seizures and > 7 seizures/week, who had not responded to
≥ 2 AEDs who had not previously been treated with a KD. Study conducted in the UK. All seizure types
included;
• Exclusion criteria: hyperlipidaemia, renal stones or organic acid deficiency syndromes.
Interventions • Participants were randomised to commence a KD (either classic or MCT) immediately (73 participants)
or after a further 3 months of seizure recording (usual care group, 72 participants). Those in the KD
arm were then randomised to receive classical KD or MCT;
• 4:1 refers to 4 g fat to 1 g of carbohydrate and protein combined.
Neal 2008 
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Outcomes • Reduction in seizure frequency;
• Tolerability.
Notes • Of the 65 who commenced the diet, 10 dropped out. Of these, 6 had poor dietary tolerance, 3 with-
drew due to parental unhappiness, 1 increased seizures and 1 excluded due to inadequate data. In the
control group, 15 participants were excluded due to inadequate data;
• This study received financial support from HSA, Smiths Charity, Scientific Hospital Supplies, and the
Milk Development Council. University College London Institute of Child Health received funding as a
National Institute for Health and Research Specialist Biomedical Research Centre.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Minimisation method with stratification.
Allocation concealment
(selection bias)





High risk Open-label study meaning participants and personnel were not blinded.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Open-label study meaning outcome assessors were not blinded.
Incomplete outcome data
(attrition bias)
Low risk High level of missing data in usual care group, however, completed ITT.
Selective reporting (re-
porting bias)
Low risk Initial application protocol received. No evidence to suggest selective report-
ing.





Methods Randomised, non-blinded, open-label, parallel controlled trial, to compare a 4:1 and a 2.5:1 ratio KD
over a 3-month period.
Participants • 38 children aged 6 months to 5 years, with drug-resistant epilepsy, at least 2 seizures/month, despite
appropriate use of at least 2 AEDs and at least 1 newer AED. Study undertaken in India;
• Exclusion criteria: known or suspected inborn errors of metabolism, systemic illness or surgical reme-
diable causes of epilepsy;
• Epilepsy syndromes included were West syndrome (9 participants in 4:1 KD group and 7 participants
in 2.5:1 KD group), Lennox-Gastaut syndrome (8 participants in 4:1 KD group and 9 participants in 2.5:1
KD group), Doose (no participants in 4:1 KD group and 2 participants in 2.5:1 KD group) and unclassi-
fied syndromes (2 participants in 4:1 KD group and 1 participant in 2.5:1 KD group). The trial included
participants with cerebral palsy (15 participants in 4:1 KD group and 9 participants in 2.5:1 KD group).
Raju 2011 
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Interventions • Participants were randomised into 1 of 2 groups; a 4:1 ratio KD (19 participants) and 2.5:1 KD (19 par-
ticipants) and followed for 3 months;
• 4:1 refers to 4 g fat to 1 g of carbohydrate and protein combined. 2.5:1 refers to 2.5 g fat to 1 g of
carbohydrate and protein combined.
Outcomes • > 50% reduction in seizure frequency;
• Adverse effects;
Notes • 3 participants in each group dropped out of the study. Reasons for drop out in 4:1 KD group were
refusal to eat, unsatisfactory seizure control and non-acceptance by other family members. In 2.5:1
KD group, 2 participants dropped out due to unsatisfactory seizure control and 1 due to refusal to eat;
• No funding was received for this study.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Sequence generation was computer generated.
Allocation concealment
(selection bias)





High risk Open-label study meaning participants and personnel were not blinded.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Open-label study meaning outcome assessors were not blinded.
Incomplete outcome data
(attrition bias)




Unclear risk Protocol unavailable.






Methods Single-centre randomised controlled trial, to compare 3:1 and 4:1 KD. Baseline period lasted 2 months.
After a 3-month period of the diet, participants who were seizure free in the 4:1 group were recom-
mended to change to a 3:1 ratio, and participants who were not seizure free in the 3:1 group were rec-
ommended to change to a 4:1 ratio and were re-evaluated after a further 3 months.
Participants • 76 children (aged 4 months to 16 years), with > 4 seizures/month and seizures were not controlled by
at least 3 AEDs. Study completed in Korea. All seizure types included;
• Exclusion criteria: children with metabolic disorders, known or suspected neurological degenerative
disorders, or both;
Seo 2007 
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• Epilepsy syndromes included Lennox-Gastaut syndrome and the study also included participants with
infantile spasms
Interventions • Participants were randomised into 2 groups, 4:1 KD group (40 participants) and 3:1 KD group (36 par-
ticipants) and the diet was followed for 3 months;
• 4:1 refers to 4 g fat to 1 g of carbohydrate and protein combined. 3:1 refers to 3 g fat to 1 g carbohydrate
and protein combined;
• After a three-month period of the diet, children who were seizure free in the 4:1 group were recom-
mended to change to a 3:1 ratio, and children who were not seizure free in the 3:1 group were recom-
mended to change to a 4:1 ratio and re-evaluated after a further three months.
Outcomes • Seizure reduction rate;
• Tolerability.
Notes • 6 participants dropped out in both of the original groups. 2 participants in the 3:1 group dropped out
due to diet intolerance and 1 participant in the 4:1 KD group. 1 participant in the 3:1 group dropped
out due to acute pancreatitis. Other reasons for drop out of participants were not stated;
• This study was financially supported by Yonsei University Research Fund of 2003.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Although study stated that participants were randomly assigned to each
group, there was no information regarding how randomisation was achieved.
Allocation concealment
(selection bias)





High risk Blinding was not discussed in this paper, but considering the design of the
study, blinding of participants and study personnel does not seem possible.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Blinding was not discussed in this paper, but considering the design of the
study, blinding of outcome assessors does not seem possible.
Incomplete outcome data
(attrition bias)




Unclear risk Protocol unavailable.





Methods Open-label, single-centre, parallel-group, randomised controlled trial, to compare the MAD to a usu-
al care group over a 3-month period. Authors noted the study design to be similar to that of Neal 2008.
There was a 4-week baseline of seizure frequency.
Participants • 102 children aged 2-14 years with drug-resistant epilepsy and 2-14 daily seizures, having previously
tried 3 AEDs. Study conducted in India;
Sharma 2013 
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• Exclusion criteria: known or suspected inborn errors of metabolism, systemic illness or motivational
issues the family that would prelude compliance;
• Epilepsy syndromes included: West syndrome (9 participants in the MAD group and 10 participants in
usual care group) and myoclonic astatic epilepsy (2 participants in the MAD group and 3 participants
in usual care group).
Interventions Randomised into 1 of 2 groups; MAD (50 participants) or a normal diet (52 participants) for a period of 3
months.
Outcomes • Seizure frequency;
• Tolerability;
• Adverse effects.
Notes • 4 children reported to have dropped out of the trial. 2 secondary to lower respiratory tract infections,
1 secondary to hyperammonaemic encephalopathy and 1 as the child and family found the diet too
restrictive. In the usual care group, 3 participants were lost to follow-up;
• The lead author (Sharma) was financially supported as a Senior Research Associate in the “Scientists
pool scheme” of the Council for Scientific and Industrial Research (CSIR), Government. of India, for
this study.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation sequence was computer generated.
Allocation concealment
(selection bias)





High risk Open-label study meaning participants and personnel were not blinded.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Open-label study meaning outcome assessors were not blinded.
Incomplete outcome data
(attrition bias)
Low risk Study attrition reported and ITT analysis carried out.
Selective reporting (re-
porting bias)
Low risk Protocol available 15 August 2015 (NCT00836836).





Methods Prospective, randomised, non-blinded controlled trial to compare sMAD to usual care (normal diet).
Four-week baseline period completed.
Participants • 81 participants aged 2-14 years, with drug-resistant epilepsy, experiencing daily seizures (or more than
7 seizures per week) despite 2 or more AEDs. Study was conducted in India;
Sharma 2016 
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• Exclusion criteria: known or suspected inborn errors of metabolism, systemic illness, surgically reme-
diable causes of epilepsy, motivational issues in the family that would preclude compliance;
• Epilepsy syndromes included West syndrome (22 participants in sMAD and 25 participants in the nor-
mal diet group) and Lennox-Gastaut syndrome (14 participants in sMAD and 13 participants in usual
care group).
Interventions • Randomised into 1 of 2 groups; sMAD (10 g carbohydrate per day, delivered with simplified dietary
methods) and usual care (normal diet) for a 3-month period;
• This study modified the traditional educational techniques used to implement the diet, to promote
the inclusion of children with parents who have low levels of literacy and who are of poor socioeco-
nomic status.




Notes • At 3 months 5 participants dropped out of the trial in the sMAD arm; 1 participant 'changed their mind'
after randomisation, 2 were lost to follow-up and 2 discontinued the diet. Reasons for discontinuation
included refusal to eat and anorexia with lethargy. In the usual care group 1 participant was lost to
follow-up;
• This study was supported by the Indian Council of Medical Research (ICMR).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









High risk Open-label study meaning participants and personnel were not blinded.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Open-label study meaning outcome assessors were not blinded.
Incomplete outcome data
(attrition bias)
Low risk Study attrition reported and ITT analysis carried out.
Selective reporting (re-
porting bias)
Low risk Protocol received. No evidence to suggest selective reporting.
Other bias Low risk A subjective, non-validated tool was used to assess alertness, speech, sleep-







Ketogenic diets for drug-resistant epilepsy (Review)









Cochrane Database of Systematic Reviews
Methods Prospective, randomised, non-blinded, controlled trial to compare MAD to usual care over a 2-month
period.
Participants • 66 adult participants aged 18 years or over, with drug-resistant epilepsy (2 or more AEDs and 2 or more
seizures per month). Study was conducted in Iran;
• Exclusion criteria: prior use of the Atkins' diet or MAD for 1 week or more, use of KD within the last
year, heart disease, renal disease, hypercholesterolaemia, coronary heart diease, cerebral vascular
disease, peripheral vascular disease, atherosclerosis, myocardial infarction, pregnancy, BMI < 18.5 kg/
m2, status epilepticus in last 6 months and 2-week seizure-free period in last 6 months.
Interventions Randomised into 1 of 2 groups; MAD (carbohydrates limited to 15 g per day; approximate macronutri-
ent intakes as a percentage of total energy: 4% to 6% carbohydrate, 20% to 30% protein, 60% to 70%
fat) and usual care for a 2-month period.
Outcomes • Seizure reduction;
• Adverse effects.
Notes • At 2 months 12 participants dropped out of the MAD arm, all due to non-compliance;
• The study was supported by the Plastic Surgery Research Centre, Isfahan University of Medical
Sciences, Isfahan.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number table.
Allocation concealment
(selection bias)





High risk Open-label study meaning participants and personnel were not blinded.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Open-label study meaning outcome assessors were not blinded.
Incomplete outcome data
(attrition bias)
Low risk Study attrition reported and ITT analysis carried out.
Selective reporting (re-
porting bias)
Unclear risk Protocol unavailable.
Other bias High risk Numerical errors with the article. No power calculation stated. Low levels of
urinary ketosis achieved, may impact efficacy data. Unknown if baseline peri-
od completed prior to commencing diet.
Zare 2017  (Continued)
AED: antiepileptic drug; BMI: body mass index; Fast FD: fasting-onset ketogenic diet; Grad KD: gradual-onset ketogenic diet; ITT: intention-
to-treat; KD: ketogenic diet; MAD: modified Atkins diet; MCT: medium-chain triglyceride; QALYs: quality-adjusted life years; SD: standard
deviation; sMAD: simplified modified Atkins diet.
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Study Reason for exclusion
Dressler 2015 Irrelevant study population - infantile spasms.
Freeman 1999 Outcome measures did not match inclusion criterion as duration of study was 12 days.
Freeman 2009 Study was very brief and lasted only 12 days - duration of the study did not fit entry criteria.
Hemingway 2001 Not a randomised controlled trial.
Kang 2011 Drug-resistant infantile spasm population, outcome measures did not match inclusion criteria for
this review.
NCT03183076 We suspect that the study was non-randomised.
Singh 2015 Abstract only. Unable to obtain further data.
Smith 2011 Not a randomised controlled trial.
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Modified Atkins diet in adolescence and adults with drug-resistant epilepsy
Methods An unblinded, randomised controlled trial.
Participants Aimed to recruit 160 people, aged 10 to 55 years, with drug-resistant epilepsy. Included partici-
pants experiencing persistent, daily countable seizures (more than 2 per month for 6 months), will-
ing to attend regular follow-up and maintain seizure frequency accurately and willing to perform
induction phase of diet. Potencial participants excluded if less than 10 years of age, surgically re-
mediable causes of epilepsy, clinical features of inborn metabolism, suspicion of a metabolic dis-
order, refusal to give consent, tried KD in past year, BMI < 18 and > 30 kg/m2, two or more of the fol-
lowing: high blood ammonia (> 80 mmol/L), high arterial lactate (> 2 mmol/L), metabolic acidosis
(pH > 7.2), hypoglycaemia (< 40 mg/dL)
Interventions • Intervention group treated with MAD (20 g carbohydrate per day) for 6 months;
• Control arm receive normal diet with no dietetic input for 6 months, following which MAD can be
offered.
Outcomes Primary outcome:
• Greater than 50% seizure reduction at 6 months;
Secondary outcomes:
• Rate and characteristics of short-term adverse effects while on MAD;
• Rate of withdrawal from the MAD diet during the study period and reasons for withdrawal;
• Change in quality of life of both groups during the study period.
Starting date 18 August 2015
Contact information manjari2tripathi@gmail.com
Notes Recruitment expected to be complete June 2018.
CTRI/2015/07/006048 
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Study name Effect of modified Atkins diet when compared to low glycemic index diet in controlling seizures in
children with epilepsy who do not respond to conventional anti epileptic drugs
Methods A randomised, controlled, parallel group trial.
Participants • Intends to recruit 90 children, aged 6 months to 5 years old with drug-resistant epilepsy (failure
of adequate trials of two tolerated, appropriately chosen drug schedules);
• Exclusion criteria: Children with renal, pulmonary, cardiac or hepatic dysfunction, severe malnu-
trition (according to the World Health Organization).
Interventions • Intervention group treated with MAD (10 to 20 mg carbohydrate per day);
• Control arm treated with low glycaemic index foods.
Outcomes Primary outcome:
• Seizure freedom (as per parental reports) at 4 weeks and 12 weeks;
Secondary outcomes:
• Rate and characteristics of adverse effects while on MAD at 4 weeks and 12 weeks;
• Greater than 50% seizure reduction (as per parental reports) at 4 weeks and 12 weeks;
• Greater than 90% seizure reduction (as per parental reports) at 4 weeks and 12 weeks.
Starting date 1 January 2018
Contact information jayashankarkaushik@gmail.com




Study name The modified Atkins diet in patients with refractory epilepsy and intellectual disability: a ran-
domised controlled trial
Methods A single-centre, parallel, unblinded randomised controlled trial.
Participants • Aimed to recruit 54 people, aged > 18 years, adults with drug-resistant epilepsy that was controlled
by 2 AEDs;
• Included participants must have had ≥ 2 seizures/month and have moderate-to-severe intellec-
tual disability;
• Exclusion criteria: participants who have undergone epilepsy surgery in the last 6 months or were
awaiting surgery; underwent implantation of vagal nerve stimulation in the last 6 months; have
used the MAD or KD for > 7 days in the last year.
Interventions • Intervention group treated with the MAD for at least 4 months, with a total follow-up of at least
6 months;
• Control group comprised a waiting list in which participants can begin the MAD diet after the 4-
month trial period, the control group can be started on the MAD as well, in which efficacy, tolera-
bility and safety will also be evaluated.
Outcomes Primary outcome:
• Number of responders 4 months after randomisation, compared between the intervention and
the control group. Responder is defined by > 50% reduction in seizure frequency;
Hulshof 2017 
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Secondary outcomes:
• Retention of the diet;
• Change in daily functioning;
• Feasibility of the MAD in this population and setting;
• Adverse effects attributable to the MAD;
• Predictive factors of efficacy of the diet.
Starting date Unknown
Contact information Unknown
Notes On 28 July 2015, the study authors reported that this trial was ongoing and was now recruiting
from an additional site. They expect to end recruitment at the end of July 2016. No further update




Study name Dietary therapy in epilepsy treatment (Diet-trial): a randomised non-inferiority trial comparing KD,
MAD and LGIT for drug resistant epilepsy
Methods A randomised, parallel-group trial.
Participants Intend to recruit 170 children aged 1 to 15 years, who experience four seizures or more per month,
despite treatment with two or more AEDs and who have not previously tried a KD, MAD or LGIT diet
Interventions • First intervention group received KD for 24 months;
• Second intervention group received MAD for 24 months;
• Third intervention group received LGIT for 24 months.
Outcomes Primary outcome:
• Percentage seizure reduction from baseline at 24 months;
Secondary outcomes:
• Adverse effects.
Starting date April 2016
Contact information Prof Sheffali Gulati





Study name Comparison between efficacy of daily and intermittent low glycaemic index therapy diet among
children with drug resistant epilepsy aged 1-15 years: an open labeled randomized controlled par-
allel design non-inferiority trial
Methods An open-label, randomised, controlled, parallel-group design, non-inferiority trial.
NCT03464487 
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Participants • Aim to enrol 110 children, aged 1 to 15 years, with drug-resistant epilepsy who were willing to
attend regular follow-up;
• Exclusion criteria: if there was a surgically remediable cause for their epilepsy, a proven inborn
error of metabolism except in which dietary therapy for epilepsy is indicated (i.e. pyruvate car-
boxylase deficiency and glucose transporter type 1 (GLUT 1) deficiency), previously received KD,
MAD or LGIT diet, had chronic kidney disease, chronic liver disease/gastrointestinal illness, chron-
ic heart disease (congenital and acquired), or a chronic respiratory illness.
Interventions • Intervention group received daily LGIT, alongside AEDs (40 g to 60 g carbohydrate per day, carbo-
hydrates required to have glycemic index less than 50) for 6 months;
• Intervention group received daily LGIT for five days of each week, alongside AEDs, plus two days
of liberal diet (40 g to 60 g carbohydrate per day for five days per week, carbohydrates required
to have glycemic index less than 50) for 6 months.
Outcomes Primary outcome:
• Percentage of seizure reduction from baseline at 24 weeks;
Secondary outcomes:
• Greater than 50% seizure reduction at 6 months;
• Improvement in social quotient at 6 months, measured by Vineland Social Maturity scale;
• Rate of adverse effects at 3 months and 6 months;
• Correlation between seizure frequency and change with blood haemoglobin A1c levels at 3
months and 6 months;
• Correlation between seizure frequency and change with blood betahydroxybutyrate levels at 3
months and 6 months;
• Rate of biochemical adverse effects at 6 months.
Starting date 15/02/2018
Contact information sheffaligulati@gmail.com
Notes Estimated study completion date was January 2019 however, at the time of publishing, the Clini-




Study name Comparison of efficacy of LGIT and MAD among children with drug resistant epilepsy
Methods An open-label randomised, non-inferiority trial with parallel-group design
Participants • Intend to enrol 110 children, aged 1 to 15 years with drug-resistant epilepsy, willing to come for
regular follow-up, seizure frequency > 4 seizures per month, receiving optimal doses of ≥ 2 AEDs.
For West syndrome, participants required to have ≥ 4 spasm cluster per month despite treatment
with AEDs and adrenocorticotrophic hormone or vigabatrin;
• Participants excluded if they had a surgically remediable cause for their epilepsy, an inborn error
of metabolism, previously received KD, MAD or LGIT diet, had chronic kidney disease, chronic liv-
er disease/gastrointestinal illness, chronic heart disease (congenital and acquired), or a chronic
respiratory illness.
Interventions • Intervention group received LGIT (food items with glycaemic index < 50 only) for 24 weeks;
• Intervention group received MAD (20 g carbohydrate per day, increased fat and protein ratio) for
24 weeks.
NCT03764956 
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Outcomes Primary outcome:
• Percentage seizure reduction from baseline to 24 weeks;
Secondary outcomes:
• Greater than 50% seizure reduction at 24 weeks;
• Rate of adverse effects at 24 weeks;
• Compliance assessed each week (satisfactory or unsatisfactory);
• Change in social quotient at 24 weeks measured by Vineland Social Maturity scale;
• Change in quality of life of participants < 4 years measured by Pediatric Quality of Life inventory
at 24 weeks;
• Change in quality of life of participants ≥ 4 years measured by Quality of Life in Childhood Epilepsy
questionnaire at 24 weeks;
• Change in quality of life of caregivers measured by the World Health Organization Quality of Life
questionnaire at 24 weeks;
• Gut microbiota analysis pre- and post-dietary therapy at 24 weeks;








Study name Evaluation of the modified Atkins diet in children with epileptic spasms refractory to hormonal
therapy: a randomised controlled trial
Methods An open-label, randomised, controlled, parallel-group design trial.
Participants • Intend to enrol 90 children, aged 9 months to 3 years, with epileptic spasms in clusters and evi-
dence of hypsarrhythmia or its variants on EEG, at least one or more cluster(s) per day despite
treatment with oral corticosteroids or adrenocorticotrophic hormone (ACTH) and one addition-
al anticonvulsant (valproate/benzodiazepine/vigabatrin/topiramate/zonisamide/levetiracetam)
for at least 4 weeks;
• Exclusion criteria: Children with an error of known or suspected metabolism, or they had renal,
pulmonary, cardiac, or hepatic dysfunction, severe malnutrition, motivational or psychosocial is-
sues in the family which may affect compliance.
Interventions • Intervention group are treated with MAD (10 g carbohydrate per day) for 1 month;
• Control arm receive normal diet with no dietetic input for 1 month.
Outcomes Primary outcome:
• Seizure freedom (as per parental reports) at 4 weeks;
Secondary outcomes:
• Greater than 50% seizure reduction (as per parental reports) at 4 weeks;
• Resolution of hypsarrhythmia on EEG at 4 weeks;
• Rate and characteristics of adverse effects as (per parental reports) while on MAD.
NCT03807141 
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Starting date 15 January 2019
Contact information sharma.suvasini@gmail.com





Study name Ketogenic diet in the treatment of epilepsy in children under the age of 2 years:
Methods An open-label, randomised, controlled, multi-centre trial.
Participants Intend to recruit 160 children, aged 3 months up to 24 months, with confirmed diagnosis of epilep-
sy, specifically, drug-resistant epilepsy (failure of two AEDs) and includes infantile spasms. Seizure
frequency required to be ≥ 4 seizures per week on average.
Interventions • Intervention group treated with classical ketogenic diet (at least a 3:1 ratio for fat to carbohydrate
and protein) for 8 weeks up to 12 months;
• Control arm will receive further antiepileptic drugs (the most appropriate further AED for the indi-
vidual child as chosen by the expert clinician) plus a discussion regarding diet and healthy eating.
Outcomes Primary outcome:
• Change in seizure frequency from baseline to weeks 6-8;
Secondary outcomes:
• Seizure freedom at 8 weeks;
• Greater than 50% seizure reduction at 8 weeks;
• Tolerance to KD (assessed by adverse effects questionnaire) at 8 weeks;
• Rate of biochemical adverse effects at 8 weeks;
• Relationship between medium-chain fatty acids and seizure control at 8 weeks;
• Retention rate at 12 months;
• Quality of life (Infant Toddler Quality of Life Questionnaire) at 12 months;
• Neurodevelopmental outcome (Vineland Adaptive Behaviour Scales) at 12 months.
Starting date January 2015
Contact information s.titre-johnson@ucl.ac.uk
Notes • ClinicalTrials.gov identifier (NCT number): NCT02205931;
• Estimated study completion was June 2019, however, at the time of publishing, the ClinicalTrial-
s.gov entry reported that the study was still recruiting participants.
Titre-Johnson 2017 
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Comparison 1.   Ketogenic diet versus usual care





Statistical method Effect size
1.1 Seizure freedom: children 4 385 Risk Ratio (M-H, Fixed, 95% CI) 3.16 [1.20, 8.35]
1.2 Seizure freedom: adults 2 141 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.3 50% or greater reduction in seizure fre-
quency: children
4 385 Risk Ratio (M-H, Fixed, 95% CI) 5.80 [3.48, 9.65]
1.4 50% or greater reduction in seizure fre-
quency: adults
2 141 Risk Ratio (M-H, Random, 95% CI) 5.03 [0.26, 97.68]
1.5 Treatment withdrawal: children 5 425 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.74, 1.57]
1.6 Treatment withdrawal: adults 2 141 Risk Ratio (M-H, Random, 95% CI) 5.38 [0.42, 69.53]
 
 








Heterogeneity: Chi² = 1.58, df = 3 (P = 0.66); I² = 0%
Test for overall effect: Z = 2.32 (P = 0.02)


































M-H, Fixed, 95% CI
1.45 [0.26 , 8.02]
2.96 [0.12 , 71.47]
11.43 [0.65 , 201.50]
2.93 [0.63 , 13.65]
3.16 [1.20 , 8.35]
Risk Ratio
M-H, Fixed, 95% CI
0.005 0.1 1 10 200
Favours usual care Favours ketogenic diet
 
 







Test for overall effect: Not applicable


























M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours usual care Favours ketogenic diet
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Analysis 1.3.   Comparison 1: Ketogenic diet versus usual care,








Heterogeneity: Chi² = 0.76, df = 3 (P = 0.86); I² = 0%
Test for overall effect: Z = 6.76 (P < 0.00001)


































M-H, Fixed, 95% CI
4.83 [1.16 , 20.10]
6.90 [2.55 , 18.69]
4.51 [2.03 , 10.01]
7.48 [2.44 , 22.96]
5.80 [3.48 , 9.65]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours usual care Favours ketogenic diet
 
 
Analysis 1.4.   Comparison 1: Ketogenic diet versus usual care,






Heterogeneity: Tau² = 3.27; Chi² = 3.33, df = 1 (P = 0.07); I² = 70%
Test for overall effect: Z = 1.07 (P = 0.29)
























M-H, Random, 95% CI
1.54 [0.27 , 8.70]
23.57 [1.45 , 382.39]
5.03 [0.26 , 97.68]
Risk Ratio
M-H, Random, 95% CI
0.002 0.1 1 10 500
Favours usual care Favours ketogenic diet
 
 









Heterogeneity: Chi² = 3.31, df = 4 (P = 0.51); I² = 0%
Test for overall effect: Z = 0.38 (P = 0.71)







































M-H, Fixed, 95% CI
1.20 [0.25 , 5.78]
1.18 [0.58 , 2.40]
0.81 [0.49 , 1.36]
1.39 [0.33 , 5.89]
4.88 [0.60 , 39.93]
1.08 [0.74 , 1.57]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours ketogenic diet Favours usual care
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Heterogeneity: Tau² = 2.53; Chi² = 3.29, df = 1 (P = 0.07); I² = 70%
Test for overall effect: Z = 1.29 (P = 0.20)
























M-H, Random, 95% CI
2.23 [0.95 , 5.23]
23.57 [1.45 , 382.39]
5.38 [0.42 , 69.53]
Risk Ratio
M-H, Random, 95% CI
0.002 0.1 1 10 500
Favours ketogenic diet Favours usual care
 
 
A P P E N D I C E S
Appendix 1. CRS Web search strategy
1. MESH DESCRIPTOR Epilepsy EXPLODE ALL WITH QUALIFIER DH AND CENTRAL:TARGET
2. MESH DESCRIPTOR Seizures EXPLODE ALL WITH QUALIFIER DH AND CENTRAL:TARGET
3. #1 OR #2
4. MESH DESCRIPTOR Diet Therapy EXPLODE ALL AND CENTRAL:TARGET
5. MESH DESCRIPTOR Fasting EXPLODE ALL AND CENTRAL:TARGET
6. (ketogenic* OR diet OR diets OR dieting):AB,KW,MC,MH,TI AND CENTRAL:TARGET
7. #4 OR #5 OR #6
8. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
9. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
10. (epilep* OR seizure* OR convuls*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
11. #8 OR #9 OR #10 AND CENTRAL:TARGET
12. #7 AND #11
13. #3 OR #12
Appendix 2. MEDLINE search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials published in the Cochrane
Handbook for Systematic Reviews of Interventions (Lefebvre 2011).
1. exp Epilepsy/dh [Diet Therapy]
2. exp Seizures/dh [Diet Therapy]
3. 1 or 2
4. exp Diet Therapy/
5. exp Fasting/
6. (ketogenic$ or diet? or dieting).tw.
7. 4 or 5 or 6
8. exp Epilepsy/
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9. exp Seizures/
10. (epilep$ or seizure$ or convuls$).tw.
11. 8 or 9 or 10
12. exp *Pre-Eclampsia/ or exp *Eclampsia/
13. 11 not 12
14. 7 and 13
15. 3 or 14
16. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
17. clinical trials as topic.sh.
18. trial.ti.
19. 16 or 17 or 18
20. exp animals/ not humans.sh.
21. 19 not 20
22. 15 and 21
23. remove duplicates from 22
W H A T ' S   N E W
 
Date Event Description
29 April 2019 New search has been performed We updated the searches on 29 April 2019 and included two new
studies (Kverneland 2018; McDonald 2018)




H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 3, 2003
 
Date Event Description
11 April 2017 New citation required but conclusions
have not changed
Conclusions are unchanged
11 April 2017 New search has been performed We updated the searches on 11 April 2017 and included four new
studies (Lambrechts 2017; Kim 2016; Singh 2015; Zare 2017)
30 March 2015 New citation required but conclusions
have not changed
Conclusions are unchanged
30 March 2015 New search has been performed We updated the searches on 30 March 2015 and included three
new studies (El-Rashidy 2013; Raju 2011; Sharma 2013)
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Date Event Description
28 May 2012 Amended New Summary of Findings table added
28 January 2012 New citation required but conclusions
have not changed
Review updated
28 January 2012 New search has been performed We updated this review. We included four new RCTs. We also
identified seven prospective studies and four retrospective stud-
ies.
 
C O N T R I B U T I O N S   O F   A U T H O R S
Kirsty J Martin-McGill (KM) was responsible for the update of this review.
Rebecca Bresnahan (RB) provided support for the update of this review.
Robert G Levy (RL) provided expert opinion and feedback for the update of this review.
Paul N Cooper (PC) provided expert opinion and feedback for the update of this review.
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S O U R C E S   O F   S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research (NIHR), UK
This review update was funded by the National Institute for Health Research (NIHR) [Clinically eIective treatments for central nervous
system disorders in the NHS, with a focus on epilepsy and Movement Disorders] (SRPG project 16/114/26). The views expressed are
those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We have updated the methods, results, discussion, conclusion and recommendation sections due to the addition of new studies. This is
the second title change since the protocol was published.
This most recent review update was undertaken at the request of the National Institute for Health and Care Excellence (NICE). NICE
guidelines include pathways for epilepsy populations with intellectual disabilities. Consequently, for this review update, we also attempted
to assess KD interventions in this epilepsy population specifically for the first time.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Diet, Carbohydrate-Restricted  [methods];  Diet, Ketogenic  [adverse eIects]  [*methods];  Dietary Carbohydrates  [*administration &
dosage];  Dietary Fats  [*administration & dosage];  Drug Resistant Epilepsy  [*diet therapy];  Intention to Treat Analysis;  Prospective
Studies;  Randomized Controlled Trials as Topic;  Retrospective Studies
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MeSH check words
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